Identification and functional characterization of a mouse lymphotoxin beta-receptor like protein by Seegers, Silvia
 1
 
Identification and Functional Characterization of a 
Mouse Lymphotoxin β-Receptor Like Protein 
 
Thesis submitted for the degree of 
Master of Philosophy 
at the University of Leicester 
 
 
 
by 
 
 
 
Silvia Seegers  
Institute of Immunology 
University of Regensburg 
Department of Infection, Immunity & Inflammation  
University of Leicester 
 
 
 
 
 
 
© Silvia Seegers, 20.12.2004. 
This thesis is copyright material and no quotation from it may be 
published without proper acknowledgement. 
 2
Acknowledgement 
 
I am grateful to Prof. Daniela Maennel for giving me the opportunity to do my 
Master’s degree in her institute and for her readiness to answer questions and 
provide assistance whenever needed. 
 
I would like to thank Prof. Wilhelm Schwaeble who gave the impetus for my project 
by offering to supervise my work. 
 
The idea for this project was provided by PD Dr. Thomas Hehlgans whose 
willingness to discuss the project and to critically read the manuscript was very 
helpful; thank you, Thomas.  
 
I would like to thank Valeria Runza for critically reading the manuscript and for her  
helpful suggestions. 
 
Dr. Gero Brockhoff spent a lot of time teaching me how to perform four colour flow 
cytometric analyses and in discussing the results; thank you very much, Gero. 
 
Thanks to everybody in the lab who helped with experience, ideas and discussions 
during these two years. 
 
I acknowledge gratefully Prof. Reinhard Buettner’s patience and trust in earlier 
times in guiding me to molecular biology and in teaching me how to perform good 
research.  
 
Finally, I owe a very special debt to Prof. Ferdinand Hofstädter who has supported 
my professional development in every possible way for 18 years now. 
 
 
                                                                                                        Table of contents 
 3
 Acknowledgement............................................................................................2 
 Abbreviations ...................................................................................................5 
1. Introduction ......................................................................................................9 
1.1. The TNF/TNFR superfamily .........................................................................9 
1.1.1. The ligands of the TNF/TNFR superfamily..............................................11 
1.1.2. The receptors of the TNF/TNFR superfamily ..........................................11 
1.1.2.1. TRAF binding receptors ......................................................................12 
1.1.2.2. Death receptors...................................................................................13 
1.1.2.3. Decoy receptors ..................................................................................15 
1.2. The lymphotoxin β receptor (LTβR) and its ligands ....................................16 
1.2.1. Structure of the LTβR .............................................................................16 
1.2.2. Expression of the LTβR ..........................................................................17 
1.2.3. Ligands of the LTβR ...............................................................................17 
1.2.4. Expression of the ligands........................................................................17 
1.2.5. Signal transduction .................................................................................18 
1.2.6. Biological functions of the LTβR .............................................................19 
2. Prework and aim ............................................................................................22 
3. Material ..........................................................................................................24 
3.1. Companies .................................................................................................24 
3.2. Chemicals and solutions.............................................................................25 
3.3. Antibodies and sera....................................................................................26 
3.3.1. Rat anti mouse LTβR..............................................................................28 
3.4. Kits .............................................................................................................31 
3.5. Organisms ..................................................................................................31 
3.5.1. Prokaryotic cells......................................................................................31 
3.5.2. Eukaryotic cells .......................................................................................31 
3.5.3. Animals ...................................................................................................31 
3.6. Vectors .......................................................................................................32 
3.7. Primers .......................................................................................................32 
3.8. Proteins ......................................................................................................33 
3.9. Constructs ..................................................................................................34 
3.10. Prepared buffers and solutions ...............................................................35 
3.10.1. Working with cells; flow cytometry.......................................................35 
3.10.2. Molecular biology techniques ..............................................................35 
3.10.3. Media and antibiotics...........................................................................36 
3.10.4. Expression and purification of His-tagged proteins .............................37 
3.10.5. SDS-PAGE and western blots.............................................................38 
4. Methods .........................................................................................................40 
4.1. Working with thymocytes and splenocytes .................................................40 
4.1.1. Isolation of thymocytes ...........................................................................40 
4.1.2. Isolation of splenocytes...........................................................................40 
4.1.3. Cultivation of thymocytes ........................................................................41 
4.2. Flow cytometric analysis.............................................................................42 
4.2.1. Determination of the DNA profile with propidium iodide..........................42 
4.2.2. Testing of all fractions of three different anti mLTβR antibodies .............42 
4.2.3. Four colour flow cytometric analysis .......................................................43 
4.3. Molecular biology techniques .....................................................................46 
4.3.1. Cloning of the expression constructs ......................................................46 
4.3.1.1. PCR.....................................................................................................46 
4.3.1.2. Purification of DNA from PAA gels ......................................................47 
4.3.1.3. Cloning into pCR®2.1-TOPO® .............................................................47 
4.3.1.4. Small scale plasmid DNA preparation .................................................48 
                                                                                                        Table of contents 
 4
4.3.1.5. Sequencing .........................................................................................48 
4.3.1.6. Cloning into the expression vector pQE32 ..........................................49 
4.3.1.6.1. Preparation of the vector .................................................................50 
4.3.1.6.2. Preparation of the inserts.................................................................50 
4.3.1.6.3. Ligation of the truncated ECDs into pQE32 .....................................51 
4.3.1.6.4. Transformation ito M15[pREP4] E. coli............................................51 
4.3.2. Screening of a mouse thymus cDNA expression library .........................51 
4.3.3. Preparation of a cDNA library only expressing the mLTβR.....................53 
4.4. Protein chemistry techniques .....................................................................55 
4.4.1. IL2 ELISA................................................................................................55 
4.4.2. Protein assay ..........................................................................................55 
4.4.3. Prokaryotic expression and enrichment of His tagged proteins ..............55 
4.4.4. Preparation of the mLTβR from L929 cells for western blots ..................56 
4.4.5. SDS-PAGE .............................................................................................56 
4.4.6. Silver staining of the proteins after SDS-PAGE ......................................56 
4.4.7. Western blots..........................................................................................57 
4.4.8. Immunodetection of proteins on a membrane with enhanced        
chemiluminiscence ECL .............................................................................58 
4.4.9. Coomassie staining of the membrane.....................................................58 
5. Results ...........................................................................................................59 
5.1. Biological function of the unknown protein .................................................59 
5.2. Exclusion of members of the TNFR superfamily ........................................62 
5.3. Epitope mapping ........................................................................................65 
5.3.1. Cloning of the truncated ECDs ...............................................................67 
5.3.2. Expression of the truncated proteins.......................................................70 
5.3.3. Western blots and immunodetection of the truncated proteins ...............72 
5.4. Differentiation of thymocytes and splenocytes expressing the unknown 
protein ........................................................................................................77 
5.4.1. Thymocytes ............................................................................................77 
5.4.2. Splenocytes ............................................................................................86 
6. Discussion......................................................................................................95 
7. Future work ..................................................................................................100 
8. Abstract........................................................................................................102 
9. Bibliography .................................................................................................103 
                                                                                                             Abbreviations 
 5
Abbreviations  
 
aa amino acid 
ADAM a disintegrin and metalloprotease 
AIM activation inducer molecule 
AIRE autoimmune regulator gene 
AP  alkaline phosphatase 
AP1 activator protein 1 
APC allophycocyanin 
ASK1 apoptosis signal-regulating kinase 1 
BLC B lymphocyte chemoattractant 
BMMC bone marrow derived mast cells 
bp base pairs 
CD cluster of differentiation or Crohn's disease 
cDNA complementary DNA 
CRD cysteine rich domains 
CTL cytotoxic T lymphocyte 
DNA deoxyribonucleic acid 
DC  dendritic cell 
DcR decoy receptor 
DD death domain 
DED death effector domains 
DISC death inducing signaling complex 
DN  double negative thymocyte 
dNTP deoxyribonucleotide 
DP double positive thymocyte 
DR death receptor 
ECD extracellular domain 
ECL enhanced chemiluminiscence 
EDTA ethylenediaminetetraacetic acid  
ELC Epstein Barr-virus induced molecule 1 ligand chemokine 
ELISA enzyme linked immunosorbant assay 
FACS fluorescence activated cell sorter 
FADD Fas associated death domain 
FCA Flow cytometric analysis 
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FDC follicular dendritic cell 
FITC fluorescein isothiocyanate 
FSC forward scatter 
GC germinal center 
GPI glycosylphosphatidylinositol 
His histidin 
HRP horseradish peroxidase 
HSA heat stable antigen 
HVEM herpes virus entry mediator 
IBD inflammatory bowel disease 
ICD intracellular domain 
IFNγ Interferon γ 
Ig immunoglobulin 
IKK I-κB kinase 
IL-1R Interleukin 1 receptor 
IκB inhibitor of NF-κB 
IVC individually ventilated cage 
JNK c-jun N-terminal kinase 
kD kilodalton 
ko knock out 
LB medium Luria Bertani medium 
LIGHT homologous to lymphotoxins, exhibits inducible 
expression, and competes with HSV glycoprotein D for 
HVEM, a receptor expressed by T lymphocytes). 
LMP-1 latent membrane protein-1 (EBV) 
lpr lymphoproliferative A recessive mutation 
LT lymphotoxin 
LTIC lymphoid tissue inducing cell 
LTβR lymphotoxin β-receptor 
mAB monoclonal antibody 
MAPK p38 mitogen activated protein kinase 
MIP2 macrophage inflammatory protein 2 
MKK mitogen activated protein kinase (MAPK) kinase 
mLTβR mouse lymphotoxin β-receptor 
mTEC medullary thymic epithelial cell 
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MW-Std. molecular weight standard 
MZ marginal zone 
NALT nasopharyngeal associated lymphoid tissue 
NF-κB nuclear factor-κ B 
NIK NF-κB inducing kinase 1 
NK cells natural killer cells 
NP-40 Nonidet P-40 
OD optical density 
PAA polyacrylamide 
PBS phosphate buffered saline 
PCR polymerase chain reaction 
PE phycoerythrin 
PerCP-
CY5.5 
peridin chlorophyll protein-Cy5.5™ 
pfu plaque forming unit 
PI propidium iodide 
PMSF phenylmethylsulfonyl fluoride 
PMT voltage photomultiplier voltage 
PP Peyer's patches 
PVDF polyvinylidene fluoride 
RIP receptor interacting protein 
RIPA buffer radioimmunoprecipitation buffer 
ROS reactive oxygen species 
RTE recent thymic emigrants 
SAP shrimp alkaline phosphatase 
SDS-PAGE sodium dodecylsulfate polyacrylamide gel 
electrophoresis 
SLC secondary lymphoid tissue chemokine 
sp signal peptide 
SP single-positive thymocyte 
SSC side scatter 
TACE TNFα converting enzyme 
TAE buffer Tris acetate EDTA electrophoresis buffer 
TBE buffer Tris borate EDTA electrophoresis buffer 
TBS Tris buffered saline 
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TE buffer Tris EDTA buffer 
TGFβ3 transforming growth factor beta 3 
TH1, TH2 T helper 1, 2 cells 
THD TNF homology domain 
TLO tertiary lymphoid organs 
TLR Toll like receptor 
TMD transmembrane domain 
TNF tumor necrosis factor 
TNFR tumor necrosis factor receptor 
TRADD TNFR associated death domain 
TRAF TNFR associated factor 
TReg regulatory T cell 
U unit 
UC Colitis Ulcerosa 
wt mice wildtype mice 
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1. Introduction 
1.1. The TNF/TNFR superfamily 
About 30 years ago tumor necrosis factor (TNF) and lymphotoxin (LT) were 
identified as proteins expressed by activated macrophages and T cells, 
respectively, and capable of inducing tumor cell lysis (Carswell et al., 1975; Kolb 
and Granger, 1968). The first studies on TNF revealed a broad spectrum of roles 
ranging from T lymphocyte differentiation to fever and wasting. Ten years later, 
with the cloning of TNF and LT it became obvious that both proteins belong to a 
superfamily of homologous ligands and receptors, the so called TNF/TNFR 
superfamily (Gray et al., 1984; Pennica et al., 1984). Currently 19 different ligands 
and 29 different receptors are known in humans, summarized in figure 1. Over the 
years many different functions of the TNF/TNFR superfamily members were 
elucidated demonstrating critical roles in organogenesis, apoptosis, autoimmunity, 
inflammation and host defense. Members of the TNF/TNFR superfamily have also 
been found to be involved in diseases like  arteriosclerosis, autoimmune diseases 
(e.g. rheumatoid arthritis, diabetes and inflammmatory bowel disease), 
osteoporosis and cancer (Locksley et al., 2001). Knowledge of the way the ligands 
and receptors function would provide an opportunity to find pharmaceuticals for 
treating these diseases.    
In order to gain this knowledge, many different kinds of studies on different 
biological  levels were performed with the purpose of clarifying the structure and 
function of each member. 
 
 
 
 
 
Figure 1: 
Summary of all known human TNFs, linked to their receptors, according to Locksley et al., 2001; 
Bodmer et al., 2002; Ashkenazi, 2002 and Ware, 2003. 
          Ligand;           Cysteine rich domain, contributing to the extracellular domain (ECD) of the 
receptor;          Death domain, part of the intracellular domain (ICD) of some receptors 
 Arrows indicate the binding between ligand and receptor. 
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1.1.1.  The ligands of the TNF/TNFR superfamily 
Although the members of the TNF/TNFR superfamily act in variable and 
pleiotropic manners they share remarkably similar structures and conserved 
interactions.  
The TNF ligands are type II transmembrane proteins with their extracellular 
domain (ECD) at the carboxy terminus of the protein. The ECD contains a so-
called “TNF homology domain” (THD) with a sequence homology between the 
family members of ~20-30%. These THDs form trimers which are responsible for 
the receptor binding (Bodmer et al., 2002). Nearly all ligands are expressed as 
membrane bound proteins and some of them are cleaved by proteases such as 
metalloproteases of the ADAM family (adamalysins) in the case of TNF (TACE: 
TNFα converting enzyme) (Black et al., 1997) and RANKL (Lum et al., 1999), by 
members of the furin family in the case of BAFF, APRIL, TWEAK and EDA 
(Schneider et al., 1999; Chen et al., 2001) or by matrisylin, a matrix-degrading 
metalloproteinase, in the case of FasL (Powell et al., 1999). Some ligands need to 
be soluble to fulfill their physiological role such as EDA (Chen et al., 2001) 
whereas others are inhibited after shedding, for example FasL (Tanaka et al., 
1998).  LTα is directly secreted as a soluble homotrimer (LTα3) (Ashkenazi, 2002) 
or expressed on the surface of cells as a heterotrimer (LTα1β2) together with 
lymphotoxin β (LTβ) to which it is associated during biosynthesis (Ware et al., 
1995).   
1.1.2. The receptors of the TNF/TNFR superfamily 
Nearly all TNFRs are type I transmembrane proteins with their ECDs at the amino 
termini of the proteins. One to four (CD30: five) cysteine rich domains (CRD), so-
called “cysteine rich pseudorepeats”, build the ECDs of the TNFRs. With few 
exceptions in the fourth CRD each domain has six cysteine residues which build 
three intrachain disulfide bonds (Naismith and Sprang, 1998). For TNFRI, Fas and 
TRAILR2 (DR5) ligand binding in a 3:3 stoichiometry occurs in the second and the 
third CRD (Banner et al., 1993; Locksley et al., 2001; Ashkenazi, 2002).  
According to the intracellular domains (ICDs) the TNFRs can be divided into three 
different groups: first, the TNFRs with a TNFR-associated factor (TRAF) binding 
motif leading to NF-κB- (nuclear factor-κB), AP1- (activator protein 1), or NF-
κB/AP1-activation. Cell death, however, is also infrequently induced. Second, the 
“death receptors” (DR) which share a so-called “death domain” (DD), a sequence 
                                                                                                                Introduction 
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of 68 and 80 amino acids in Fas (Itoh and Nagata, 1993) and TNFRI (Tartaglia et 
al., 1993), respectively, to which adaptor molecules bind mainly for the induction of 
caspases-dependent apoptosis and rarely for the activation of NF-κB and/or AP1. 
Third, the “decoy receptors” (DcR), which lack a (functional) ICD and therefore a 
signaling pathway. None of the cytoplasmic tails of the TNFRs contain any 
enzymatic activity (Ware et al., 1995). 
Apart from these common structures there are some exceptions in the TNFR 
superfamily. BCMA, TACI, BAFFR and Xedar lack a signal peptide and are 
therefore called “type III transmembrane proteins”. TRAIL R3 (DcR1) is attached to 
the plasma membrane via a glycosylphosphatidylinositol (GPI) anchor while OPG 
and DcR3 are secreted as soluble receptors because they have no membrane-
interacting domain (Bodmer et al., 2002).  Proteolytic cleavage is found for CD27, 
CD30, CD40, TNFRI and TNFRII leading to an additional soluble active form 
(Gruss and Dower, 1995). TNFRII, CD40, Fas, and 4-1BB also exist in a 
membrane bound and in a soluble form due to alternative splicing (Lainez et al., 
2004; Papoff et al., 1996; Smith et al., 1994). These proteolytically cleaved or 
alternatively spliced receptors funtion as decoys sequestering the ligands from the 
membrane bound receptors. The low affinity p75-NGFR is the most divergent 
TNFR with no known TNF-like ligand and a propensity to dimerize rather than 
trimerize.  
1.1.2.1. TRAF binding receptors 
Many members of the TNFR superfamily initiate intracellular signaling by recruiting 
TNFR-associated factors (TRAFs) through their cytoplasmic tails. 
TRAFs constitute a family of genetically conserved adapter proteins that have 
been identified in mammals, Drosophila, Caenorhabditis elegans and 
Dictyostelium discoideum. Mammalian TRAFs (TRAF1-6) have emerged as the 
major mediators for the cell activation, cell survival, and antiapoptotic functions of 
the TNF receptor superfamily and the interleukin-1 receptor/Toll-like receptor 
superfamily (IL-1R/TLR). Binding of TRAFs to members of these two 
superfamilies, directly or indirectly via TNFR associated DD (TRADD), leads to the 
activation of NF-κB and/or AP1 (Chung et al., 2002), with one exception: the 
complex of TRAF3 and LTβR starts the apoptotic pathway (Van Arsdale et al., 
1997). Binding of TRAFs to TNFRs or IL-1Rs/TLRs takes place between 
conserved amino acid residues on the surfaces of TRAF1, 2, 3, and 5 and a 
                                                                                                                Introduction 
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structural supermotif ((P/S/T/A)x(Q/E)E) in the ICDs of the receptors. This 
supermotif and a minor motif, (PxQxxD), were found in TNFR2, CD27, CD30, 
CD40, OX40, 4-1BB, HVEM and in the human Epstein-Barr virus protein LMP-1 
(Ye et al., 1999). Binding to this supermotif was shown for TRAF2 (Ye et al., 1999) 
and TRAF3 (Ni et al., 2000).  
The signal transductions of TNFRs via TRAFs have been studied intensively but 
have not yet been clarified in every detail. Signaling via TNFR2 and TRAF2 is  
shown here as an example and in a simplified model according to Song et al., 
1997 and Wajant et al., 2001. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2: 
Signal transduction pathway via TNFR2 / TRAF2  
TRAF2 binds the activated TNFR2 and recruits either ASK1 for AP1 activation or NIK for NF-κB 
activation. 
AP1 (activator protein 1), ASK1 (apoptosis signal-regulating kinase 1), IKK (inhibitor of NF-κB (IκB) 
kinase), JNK (c-jun N-terminal kinase), NF-κB (nuclear factor-κB), NIK (NF-κB inducing kinase 1) 
1.1.2.2. Death receptors 
Apoptosis/programmed cell death is a central event during several physiological 
processes like organogenesis, inflammation and cellular immune response. Cell 
shrinkage, cytoplasmic membrane blebbing, chromatin condensation, DNA 
fragmentation and finally destruction of the cell by its disassembly into fragments 
are the characteristics of this event.  The eight death receptors (DRs) of the TNFR 
superfamily (TNFR1, Fas, TRAMP, TRAILR1, TRAILR2, DR6, p75-NGFR, and 
 
ASK1 
JNK1/2 
AP1 
NIK
IKK
TRAF2 
TNFR2 
TNF 
NF-κB
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EDAR) can trigger the apoptotic pathway through their common conserved death 
domain (DD) on their ICD.  
Upon activation of the DRs their DDs recruit various adaptor proteins (TRADD, 
FADD, and RIP) that mediate preferentially programmed cell death but in the case 
of TNFRI also proliferation. These proteins in turn recruit other proteins via their 
DDs or death effector domains (DEDs). The destruction of the cell is accomplished 
by activation of a family of proteases referred to as caspases (Ashkenazi, 2002).  
The two best studied DRs, Fas and TNFRI, are depicted in figure 3 as an example 
of the DD-depending signal cascades according to Ashkenazi, 2002, in a 
simplified model with additions described subsequently. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3: 
Signaling cascade via death domains 
FADD ( Fas-associated DD), TRADD (TNFR1-associated DD), RIP (receptor interacting protein) 
 
After binding of FasL, Fas assembles a death-inducing signaling complex (DISC): 
the recruitment of FADD activates the apoptosis-initiating proteases 8 and/or 10 
via proteolysis of their pro-caspases. TNFR1 can trigger a similar pathway after 
recruiting TRADD as an intermediate adaptor protein to its DD. TRADD finally 
binds FADD and induces apoptosis.  
The complex of TNFR1 and TRADD can also activate AP1 and NF-κB. Herr et al., 
1999 described the induction of apoptosis after JNK-activation and Wu et al., 1997 
also found RIP as an inducer of apoptosis. TRAF2 recruits IKK thereby enabling 
RIP to activate the kinases of the IKK complex (Wajant et al., 2003). So TRADD 
TRADD 
TRAF2 
JNK 
AP1 
RIP 
IKK 
TNFR1 
TNF 
NF-κB 
FADD 
FasL 
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Pro-caspase8/10
Caspase 8/10
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(?) 
                                                                                                                Introduction 
 15
seems to be the central platform where committment of the cell into either 
apoptosis or survival, proliferation and differentiation takes place. 
However, it needs to be mentioned here that recent studies have revealed that 
FADD and caspase 8 are not recruited to the TNFRI/TRADD complex for the 
induction of apoptosis and that there might be another mechanism for 
programmed cell death after TNFRI activation (Harper et al., 2003). 
1.1.2.3. Decoy receptors 
DcRs compete with membrane bound receptors for their common ligand. Three 
different forms of decoy exist. The soluble receptors DcR3 and osteoprotegerin 
(OPG) sequester their ligands either intracellularly or in the extracellular milieu 
respectively (Bhardwaj and Aggarwal, 2003). TRAIL R3 (DcR1) is anchored in the 
membrane but lacks an ICD whereas TRAIL R4 (DcR2) has only an incomplete 
DD and therefore signaling does not occur (Ashkenazi and Dixit, 1999). All these 
decoy receptors prevent binding of their ligands to membrane bound receptors 
which would start further signaling pathways.  
                                                                                                                Introduction 
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1.2. The lymphotoxin β receptor (LTβR) and its ligands 
The LTβR and its ligands are members of the TNF/TNFR superfamily and play an 
important role in the development of lymphoid cells and tissues, the maintenance 
of their structures and in cellular immunity.  
1.2.1. Structure of the LTβR 
The mouse LTβR  gene encodes for an open reading frame of 1,248 base pairs 
(415 amino acids) spanning 10 exons with 6.9kb on chromosome 6, closely linked 
to the TNFRI locus. Translation is supported by a Kozak sequence adjacent to the 
first methionine codon. Lacking a canonical TATA or a CCAAT box and with a high 
G/C content the LTβR promoter resembles a non-inducible housekeeping gene 
promoter and suggests that it is constitutively regulated (Force 1995).  However it 
has been reported that the transcription of the LTβR is upregulated in NIH 3T3 
cells, a mouse fibroblast cell line, upon stimulation with dexamethasone (Muller et 
al., 2001) and that the expression is downregulated on L929, another mouse 
fibroblast cell line, and WEHI 164 cells, a mouse fibrosarcoma cell line, after ligand 
binding or treatment with an agonistic antibody (Rennert et al., 1998). 
As a typical type I transmembrane protein, the LTβR protein consists of an amino 
terminal ECD with a signal peptide (sp) of 30 amino acids and four CRDs (193 
amino acids), a transmembrane domain (TMD) of 21 amino acids and an ICD of 
171 amino acids as depicted in chapter 5.3.2, figure 15. The ligand binding domain 
is similar to that of TNFRI in the positional arrangement of cysteine residues in a 
CxxCxxC motif and the predicted size of the loops created by the disulfide bonds 
in CRD1 and CRD2. The major contact domains for the functional ligand LTα1β2 
are CRD2 and part of CRD3. In contrast CRDs 3 and 4 of the LTβR resemble 
those of TNFRII in the positioning of the cysteine residues and by the presence of 
five additional amino acids adjacent to the ligand binding domain in CRD3. TNFRI, 
CD27, CD40, Ox40, Fas and 4-1BB contain a gap in this region. An additional 
similarity between LTβR and TNFRII is the membrane-proximal prolin-rich region 
in the ECD, which might form a stalk extending the CRDs from the cell surface 
(Force et al., 1995).  
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1.2.2. Expression of the LTβR 
Constitutively expressed mouse LTβR mRNA was found in the major visceral 
organs and lymphoid tissues including liver, lung, kidney, heart, spleen and lymph 
nodes with low expression in testis, and in cell lines of monocytic, thymic 
medullary and epithelial origin but was found neither in a cytotoxic T cell line 
(PMMI) nor in several other T cell lines, the main source of the ligand LTα1β2 
(Force et al., 1995). In addition Degli-Esposti et al., 1997 also found the human 2.1 
kb mRNA in melanoma cell lines but not in B cells or in the brain. Recently the 
LTβR was detected on bone marrow derived mast cells (BMMCs) (Stopfer et al., 
2004 ) and on activated macrophages (Ehlers et al., 2003). Taken together the 
LTβR seems to be expressed on all cell types except B and T lymphocytes; these 
cells express the ligands LTα1β2 and LIGHT (homologous to lymphotoxins, 
exhibits inducible expression, and competes with HSV glycoprotein D for HVEM, a 
receptor expressed by T lymphocytes). 
1.2.3. Ligands of the LTβR 
Up to now two functional ligands are known for the LTβR: the heterotrimeric 
lymphotoxin α1β2 (LTα1β2) and the homotrimeric LIGHT. LTα1β2 exclusively binds 
to the LTβR whereas LIGHT also binds to HVEM and DcR3 (Ware et al., 1995; 
Mauri et al., 1998). The other possible heterotrimer LTα2β1 does not seem to bind 
to the LTβR but to TNFRI (Browning et al., 1995). This complex was only found in 
vitro and its physiological role needs to be determined. There is no evidence for a 
naturally occuring LTβ3 homotrimer either (Kuprash et al., 2002). A third ligand has 
been postulated since recent studies of Boehm et al., 2003 and Muller and Lipp, 
2003 where the phenotype of mice double deficient in LTβ and LIGHT is less 
severe than the phenotype of LTβR-/- mice.   
1.2.4. Expression of the ligands 
Activated T, B and natural killer (NK) cells express soluble LTα3 and membrane 
bound LTα1β2 (Ware, 1992). 
Transcripts of LTβ were found in adult spleen and thymus and on lower levels in 
bone marrow, lung, liver, and skeletal muscle. Little or no expression was found in 
brain, heart, and testis. With in situ hybridization LTβ was also detectable in 
embryonic thymi, spleen, liver, bone marrow, and skin, and in the brain and 
cerebellum of three-week-old mice.  
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The pattern for LTα was similar in spleen and thymus (Pokholok et al., 1995).  
Interestingly, LTβ expression was detected on a subset of CD45+CD4+CD3-
IL2Rγc+IL7Rα+CXCR5+α4β7integrin+α4β1integrin+ precursor cells from fetal liver, 
called lymphoid tissue-inducing cells (LTIC), which can become natural killer cells, 
dendritic antigen-presenting cells, and eventually follicular dendritic cells, but do 
not become T or B lymphocytes. These cells are involved in the organogenesis of 
lymph nodes, Peyer’s patches (PPs) and tertiary lymphoid organs (TLO) (Mebius 
et al., 1997, 2004; Ruddle, 1999, 2004). 
LIGHT mRNA was detected in heart, placenta, liver, lung, appendix, kidney, brain, 
peripheral lymphoid tissues and predominantely in spleen but not in embryonic 
tissue, endocrine glands or tumor lines of non hematopoietic and myeloid origin 
(Mauri et al., 1998). Tamada et al., 2000 showed LIGHT expression on the surface 
of immature dendritic cells (DCs) and Morel et al., 2000 determined the 
intracellular expression of LIGHT in resting T cells and, together with the surface 
expression, in activated T cells, mainly CD8+ T cells.   
1.2.5. Signal transduction 
The LTβR has no DD but a TRAF binding motif in its ICD. Binding of TRAF2 or 
TRAF5 leads to the activation of NF-κB and AP1 (Nakano et al., 1996; Chang et 
al., 2002). 
Interestingly, in complex with TRAF3 LTβR activation - via agonistic antibodies or 
its ligands LTα1β2 and LIGHT - triggers IFNγ-dependent cell death in a subclone of 
an adenocarcinoma cell line (HT29.14S) (VanArsdale et al., 1997; Rooney et al., 
2000). 
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Figure 4:  
Signaling cascade after the activation of the LTβR, according to Chang et al., 2002; Dejardin et al., 
2002 ; Chen et al., 2003 
These signaling cascades were shown for certain cell lines and might depend on the different cell 
types. The induction of IL8 via AP1 and NFκB activation was found in HEK293 (a human 
embryonic kidney cell line) (Chang). Cell death in HT29 and Hep3BT2 (a human hepatoma cell 
line) was inducible via ROS (reactive oxygen species) with IFNγ and without IFNγ in HeLa (human 
cervical carcinoma cell line) (Chen). TRAF3 also binds NIK but does not activate NFκB (Song et 
al., 1997). 
MAPK (mitogen activated protein kinase); MKK (MAPK kinase) 
1.2.6. Biological functions of the LTβR  
The function of the LTβR was determined not only in cell culture systems but  also 
by the generation of mice deficient in the receptor itself or in its ligands. Tumanov 
et al., 2003, give a detailed summary of all these mice and their phenotypes. 
Therefore only the phenotype of the LTβR-/- mice is described here.  
Mice deficient in the LTβR lack all lymph nodes and Peyer’s patches and show 
reduced nasopharyngeal-associated lymphoid tissue (NALT) with an abnormal 
microarchitecture. Primary B cell follicles, marginal zones (MZ), germinal centers 
(GCs) and follicular dentritic cells (FDCs) are missing in the spleen where the 
segregation of  T and B cells is not developed either.  
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Treatment of adult mice with a LTβR-Ig fusion protein which sequesters the 
ligands from the endogenous LTβR destroys the splenic architecture (Mackay et 
al., 1997). This leads to the conclusion that the splenic architecture is not 
developmentally fixed but a question of continuous LTβR expression and 
activation after birth.  
In contrast, the induction of lymph node genesis seems to be dependent on the 
expression of the LTβR during embryogenesis since in-utero treatment of mice 
with LTβR-Ig fusion protein inhibits the development of lymph nodes whereas an in 
utero treatment of LTα-/- mice, which also lack all lymph nodes except occasionally 
mesenteric and cervical lymph nodes, with agonistic LTβR antibody induces the 
development of lymph nodes depending on the time of treatment (Rennert et al., 
1998).  
T and B cell development seems to be normal in LTβR-/- mice with one exception: 
mucosa patrolling αEβ7high integrin+ T cells are virtually absent (Futterer et al., 
1998). Since there are no lymph nodes to home to, T and B cells infiltrate 
perivascularly in multiple tissues (Locksley et al., 2001). 
The thymocytes appear to develop normally in the LTβR-/- mice. A retention of 
recent thymic emigrants (RTEs) can be observed, doubling the percentage of 
single positive cells in the thymus, suggesting a role for the LTβR in the control of 
the export of mature T cells. The medullary thymic epithelial cells (mTECs) in the 
thymus are reduced and show aberrant differentiation due to an impaired lympho-
epithelial cross-talk via the LTβR and due to the missing activation of NIK. mTECs 
play a crucial role in the control of autoimmunity by the promiscuous expression of 
tissue-specific antigens during negative selection. That impaired lympho-epithelial 
cross-talk was found to be associated with autoimmune phenomena suggests an 
unexpected role for the LTβR signaling in central tolerance induction (Boehm et 
al., 2003). This idea is supported by the detection of autoantibodies against DNA 
and IgG (rheumatoid factor) in five to seven-month-old LTβR-/- mice (Chin et al., 
2003), suggesting a signaling pathway in the thymus via LTβR-NIK-IKK-NFκB 
which leads to the expression of AIRE, so far the only known inducer of 
promiscuous gene expression and key mediator of central tolerance (Boehm et al., 
2003; Chin et al., 2003; Venanzi et al., 2004). The lympho-epithelial cross-talk also 
seems to be necessary for the maintenance of the three dimensional structure in 
the thymic medulla as injections with LTβR-Ig fusion protein lead to its rapid 
regression to isolated clusters of cells in mice (Boehm et al., 2003).   
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LTβR activation is also considered to be necessary for the development of natural 
killer cells (NK) (Ito et al., 1999) and dendritic cells (DC) (Wu et al., 1999) and their 
recruitment to lymphoid organs.  
Lymphoid tissue chemokines like secondary lymphoid tissue chemokine (SLC), B 
lymphocyte chemoattractant (BLC) and Epstein Barr-virus induced molecule 1 
ligand chemokine (ELC) are necessary for lymphocyte homing. Their expression in 
the spleen is dependent on the activation of the LTβR (Ngo et al., 1999).  
BMMCs release certain cytokines like IL4, IL6, TNF and RANTES after activation 
of the LTβR with an agonistic antibody or LIGHT or in coculture with activated T 
cells (Stopfer et al., 2004).  
The angiogenic CXC chemokine MIP2 is released from BFS1 cells after LTβR 
activation suggesting a role of the LTβR in tumor neoangiogenesis (Hehlgans et 
al., 2002). 
Degli-Esposti et al., 1997, and Hehlgans and Mannel, 2001 found IL8 and 
RANTES induction, loss of adherence and growth arrest after LTβR activation in 
A375, a human melanoma cell line.  
Interferon γ (IFNγ)-dependent growth arrest was induced after LTβR activation in 
some adenocarcinoma cell lines and also cell death in HT29.14S and WiDr cells 
(Browning et al., 1996; vanArsdale et al, 1997).  
Defects observed in the mucosal immune system of  mice which are deficient in 
LTα or LTβ motivated the examination of the importance of the LT/LTβR system in 
experimental colitis as a model for inflammatory bowel diseases (IBD) like Crohn’s 
disease (CD) or ulcerative colitis (UC). A protective effect with respect to wasting 
and the clinical signs of colitis in three models of IBD was determined by blocking 
the LT mediated events with a LTβR-Ig fusion protein, pointing to the lymphotoxin 
pathway as a potent intervention target for the treatment of this and maybe other 
autoimmune diseases and chronic inflammations (Mackay et al., 1998; Stopfer et 
al., 2004). Many studies have followed and are in progress in order to clarify the 
role of the LT, LIGHT/LTβR system in autoimmune diseases like IBD, diabetes or 
rheumatoid arthritis driven by the intention to find a new target for the treatment of 
these diseases.  
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2. Prework and aim 
In order to study the expression pattern of the LTβR, the molecular mechanisms 
which follow the activation of the LTβR and the role of the LT, LIGHT/LTβR system 
in a dextransulfate (DSS)-induced acute and chronic colitis model four monoclonal 
rat anti mouse LTβR antibodies and one polyclonal rabbit anti mouse LTβR serum 
were generated. The specificities of these antibodies were tested on several 
different cell lines and primary cells. NIH 3T3, L929, two mouse fibroblast cell 
lines, CFS1, BFS1, two mouse fibrosarcoma cell lines, and embryonal fibroblasts 
were known to express the LTβR. All four monoclonal antibodies (mAb) showed 
positive stainings in flow cytometric analyses whereas none of these antibodies 
bound to embryonal fibroblasts of LTβR-/- mice (Hehlgans et al., 2003).  Since it 
was known that the LTβR is not expressed on lymphocytes (Force et al., 1995), 
thymocytes of C57BL/6 mice were taken as a negative control. Surprisingly two 
mAbs, 12H11 and 1C5, showed significant shifts in flow cytometric analyses of 
these cells. Both antibodies also bound to thymocytes of LTβR-/- mice excluding 
the possibility that the thymocyte preparation was contaminated with LTβR 
expressing thymic stromal cells.  
HVEM, another member of the TNFR superfamily which binds LTα3 and LIGHT, 
was thought to be the cross-reacting protein because its ECD is 35% homologous 
to the LTβR-ECD and it is expressed on lymphocytes. Flow cytometric analyses 
on thymocytes of HVEM-/- mice still showed positive staining excluding HVEM from 
the list of possible candidates (Dr. P. Muller, personally communicated). 
The cross reactivity of 1C5 and 12H11 with thymocytes led to the question 
whether there might be another LTβR-like receptor on thymocytes which would 
bind LTα1β2 and/or LIGHT for further signaling.  
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The aim of this project was to identify and characterize this mouse LTβR-like 
protein on thymocytes with the following steps: 
- Determination whether the unknown protein has any biological function 
- Mapping the epitope to narrow down the group of probable candidates 
- Discrimination of the thymocyte subpopulations which express the unknown 
protein 
- Discrimination of the splenocyte subpopulations which express the 
unknown protein 
- Isolation of the unknown protein from thymocytes for further sequencing 
- Screening of a thymus cDNA expression library in order to clone the 
unknown protein 
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3. Material 
3.1. Companies 
Applied Biosystems Darmstadt, Germany 
BD Becton Dickinson Biosciences   Heidelberg, Germany 
Biometra Goettingen, Germany 
Biomol Hamburg, Germany 
Biorad Munich, Germany 
Charles River Sulzfeld, Germany 
Dako Glostrup, Denmark 
GE Healthcare Bio-Sciences Freiburg, Germany 
Invitrogen Karlsruhe, Germany 
Merck  Darmstadt, Germany 
Metabion Martinsried, Germany 
Millipore Schwalbach, Germany 
MoBiTec Göttingen, Germany 
NEB (New England Biolabs) Beverly, MA, USA 
PAN Biotech Aidenbach, Germany 
Promega Mannheim, Germany 
QIAGEN GmbH Hilden, Germany 
R&D Systems Wiesbaden, Germany 
Roche Applied Science Mannheim, Germany 
Carl Roth Karlsruhe, Germany 
Sigma-Aldrich Chemie Taufkirchen, Germany 
Stratagene Amsterdam, Netherlands 
The Scripps Research Institute La Jolla, CA, USA 
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3.2. Chemicals and solutions 
ABTS (2,2'-Azino-di-[3-
ethylbenzthiazoline sulfonate(6)] 
Roche Applied Science 
Agarose, electrophoresis grade Invitrogen 
Agarose, for routine use  
(Phage library) 
Sigma-Aldrich Chemie 
Ampicillin, >98% Sigma-Aldrich Chemie 
APS (Ammoniumpersulfat) Biorad 
BamHI Roche Applied Science 
BSA, Bovine serum albumin, fraction V Biomol 
Complete™ EDTA-free Roche Applied Science 
Deoxynucleotides, PCR grade Roche Applied Science 
DMSO (Dimethylsulfoxide), ACS 
reagent 
Sigma-Aldrich Chemie 
DNA-Molecular weight standards, 
X and XIV 
Roche Applied Science 
EcoRI NEB 
FCS (Fetal calf serum,  
heat inactivated) 
PAN Biotech 
Glycerol, ultrapure Gibco / Invitrogen 
Guanidiniumhydrochloride, ultra Sigma-Aldrich Chemie 
Hi-Di Formamide, Genetic Analysis 
Grade 
Applied Biosystems 
H2O Milli Q UF Plus system 
Ionomycin (1mg/ml ethanol) Sigma-Aldrich Chemie 
IPTG (Isopropyl-β-D-thiogalactoside) Biomol 
Kanamycin Gibco / Invitrogen 
KpnI Roche Applied Science 
Low fat dry milk powder Supermarket 
Methanol, technical grade Merck 
Ni-NTA (Nitrilotriacetic acid)  Agarose QIAGEN 
Nowa Solution A+B (ECL) MoBiTec 
PAA, Rotiphorese® Gel30 (37,5:1) Carl Roth 
Phenol/chloroform, for DNA purification Carl Roth 
                                                                                                                      Material 
26 
PMA (Phorbol 12-myristate 13-acetate) 
(1mg/ml ethanol) 
Sigma-Aldrich Chemie 
RNAse A, DNAse free Roche Applied Science 
RPMI-1640 Sigma-Aldrich Chemie 
SalI NEB 
SDS-PAGE Molecular weight standard, 
Broad range  
Biorad 
Shrimp alkaline phosphatase, SAP Roche Applied Science 
Sigma FAST™ BCIP/NBT (5-Bromo-4-
chloro-3-indolylphosphate/Nitroblue 
tetrazolium) 
Sigma-Aldrich Chemie 
T4 DNA ligase NEB 
Taq Polymerase Roche Applied Science 
TEMED (N, N, N, N-Tetramethyl-
ethylenediamine) 
Biorad 
Triton-X100, plus one Pharmacia / GE Healthcare Bio-Sciences 
Tryptone Difco / BD Biosciences 
TSR (Template suppression reagent) Applied Biosystems 
Tween20, p.S. Merck 
Urea, ultrapure USB / GE-Healthcare Bio-Sciences 
all other chemicals and solutions of 
analytical grade 
Sigma-Aldrich Chemie or Merck 
3.3. Antibodies and sera 
Blocking antibody/serum  
Rat anti mouse Fcy RIII/II, IgG2bκ;  
clone 2G4.2 
Institute of Immunology; University of 
Regensburg 
Normal goat serum Dako 
  
Primary antibodies  
Rabbit anti mouse LTβR,  
polyclonal serum 
Dr. P. Mueller, Institute of Immunology; 
University of Regensburg  
Rat anti mouse LTβR, IgG2a;  
clones 1C5, 12H11, 5G11b, 5D12a2 
see chapter 3.3.1 
Dr. P. Mueller, Institute of Immunology; 
University of Regensburg 
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Rat anti mouse LTβR-FITC, IgG2a;  
clone 1C5 
Dr. P. Mueller, Institute of Immunology; 
University of Regensburg 
Rat anti mouse CD3-PE, IgG2b, κ;  
clone 17A2 
Pharmingen / BD Biosciences 
Rat anti mouse CD4-PE, IgG2a, κ;  
clone RM4-5 
Pharmingen / BD Biosciences 
Rat anti mouse CD8a-APC, IgG2a, κ; 
clone 53-6.7 
Pharmingen / BD Biosciences 
Rat anti mouse CD45R/B220-PE, 
IgG2a, κ; clone RA3-6B2 
Pharmingen / BD Biosciences 
Armenian hamster anti mouse CD69-
PerCP-CY5.5,  IgG1, λ; clone H1.2F3 
Pharmingen / BD Biosciences 
Rat anti mouse CD117-PE,  IgG2b, κ; 
clone ACK45 
Pharmingen / BD Biosciences 
Mouse anti RGS-His4, IgG1  QIAGEN 
  
Isotype controls  
Armenian hamster IgG1, λ -PerCP-
CY5.5; clone A19-3 
Pharmingen / BD Biosciences 
Rat-IgG2a, κ; unlabeled or  -FITC, -PE, 
-APC; clone R35-95 
Pharmingen / BD Biosciences 
  
Secondary antibodies:  
Goat anti mouse IgG-HRP Sigma-Aldrich Chemie 
Goat anti rabbit Ig-HRP Sigma-Aldrich Chemie 
Goat anti rat IgG  Sigma-Aldrich Chemie 
Goat anti rat IgG-AP  Sigma-Aldrich Chemie 
Goat anti rat IgG-HRP Sigma-Aldrich Chemie 
Rabbit anti rat Ig, FITC Dako 
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3.3.1. Rat anti mouse LTβR  
Clone 
Purification-
Date 
Experiment-
Name 
OD280 
(mg/ml) Fraction
DC-Protein-Assay 
(mg/ml) 
FCA on 
thymocytes 
FCA on 
L929 
Western pro-
/eukaryotic Comment 
1C5 08.11.2001 P71 0.16  0.197 ++ +++ n.d.   
     0.2  0.319 +++ +++ n.d. to Dr. Walczak 
     0.3  1.11 ++ ++ n.d.    
     1.5  3.05 ++ ++ n.d.   
     2.1  3.9 ++ ++ n.d.   
     2.9  6.4 + ++ n.d.   
  30.03.2001 P19 2 F 1 6 ++ +++ n.d.   
     1 F 2 2 + +++ + (1:1000) until 01/04 
     1.3 F 3 2.74 +++ +++ + (1:1300)
until 07/04;  
FITC-labeled;  
to Dr. Wang 
     0.6 F 4 1.16 +++ +++ n.d.   
  26.06.2003    E1.1 0.486 + + n.d.   
      E1.2 1.7 + + n.d.   
      E1.3 2.91 ++ + n.d.   
      E1.4 3.81 +++ + n.d.   
      E1.5 2.23 +++ + n.d.   
      E2.1 3.94 ++ + n.d.   
      E2.2 3.13 +++ + + (1:3000) up from 08/04 
      E2.3 0.55 +++ + n.d.   
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Clone 
Purification-
Date 
Experiment-
name 
OD280 
(mg/ml) Fraction
DC-Protein-Assay 
(mg/ml) 
FCA on 
thymocytes 
FCA on 
L929 
Western pro-
/eukaryotic Comment 
12H11 08.11.2001 P72 0.7 F 3+4 1.85 - ++ n.d.   
    0.17 F 5+6 0.38 - ++ n.d.   
  10.02.2003  0.16 D 1.0 0 nd nd n.d.   
    0.18 D 2.0 0 nd nd n.d.   
    2.21 E 1.1 2.1 - + n.d.   
  1.06 E 1.2 0.67 - ++ n.d.   
  1.27 E 2.1 1.7 - ++ n.d.   
    1.24 E 3.1 1.77 - ++ n.d.   
    0.995 E 4.1 0.8 - +++ n.d.   
  03.03.2003  2.61 E 1.2 4.1 - ++ n.d.   
    0.201 E 2.1 0.08 - +++ n.d.   
  15.07.2003 27.12.2002   supern. - + n.d.   
  16.07.2003 PM06.99   supern. - + n.d.   
  14.10.2003    1.14 - + + (1:530) in use 
      0.77 - + n.d.   
      1.69 - + n.d.   
      0.26 - - n.d.   
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Clone 
Purification-
Date 
Experiment-
name 
OD280 
(mg/ml) Fraction 
DC-Protein-Assay 
(mg/ml) 
FCA on 
thymocytes 
FCA on 
L929 
Western pro-
/eukaryotic Comment 
5G11b 16.11.2001 P74 3 F4/1 (?) 6.4 - + + (1:3000) until 04/04 
     4.1 F2/2 (?) 10.9 - + n.d.   
     0.3 F1/1 v F5/2(?) 0.47 - ++ + (1:240) until 02/04 
     5.26 F3/1 (?) 12 - + n.d.   
     1.3 F3/2 (?) 2.5 - ++ + (1:1333) until 01/04 
  17.07.2003 "Standkultur"   supern. n.d. + n.d.   
   "Miniperm"  1.harvest supern. n.d. + n.d.   
   "Miniperm"  2.harvest supern. n.d. + n.d.   
   "Miniperm"  3.harvest supern. n.d. + n.d.   
  10.09.2003    E1.0 1.13 n.d. + + (1:266) up from 05/04 
      E2.0 0.36 n.d. + n.d.   
  25.09.2003    E1.1 0.39 n.d. + n.d.   
      E1.2 1.14 n.d. + n.d.   
      E1.3 1.55 n.d. + n.d.   
      E1.4 0.92 n.d. + n.d.   
5D12a2 16.11.2001 P75 0.3    n.d. n.d. n.d.   
     0.4    n.d. n.d. n.d.   
     0.5    n.d. n.d. n.d.   
     1    n.d. n.d. n.d.   
     1.1    n.d. n.d. n.d.   
     1.5    n.d. n.d. + (1:1000) in use 
     2    n.d. n.d. n.d.   
     3.7    n.d. n.d. n.d.   
     4.5    n.d. n.d. n.d.   
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3.4. Kits 
ABI Prism® BigDye™ Terminator Cycle 
Sequencing Ready Reaction Kit 
Applied Biosystems 
Dc Protein Assay Biorad 
Giga®III Gold Packaging Extract Stratagene 
IL2 ELISA "Duo Set" R&D Systems 
pBluescript®II SK(-) Phagemid Kit Stratagene 
QIAGEN Plasmid Maxi Kit QIAGEN 
TOPO TA Cloning® Kit Invitrogen 
Uni-ZAP®XR Vector Kit Stratagene 
Wizard® Plus Miniprep DNA 
Purification System 
Promega 
  
3.5. Organisms 
3.5.1. Prokaryotic cells 
Epicurian coli® XL1-Blue MRF' Stratagene 
Ex-Assist® interference resistant helper 
phage 
Stratagene 
M15 [pREP4] QIAGEN 
SOLR™ Stratagene 
TOP10 F' Invitrogen 
3.5.2. Eukaryotic cells 
L929 cells, mouse fibroblast cell line  ATCC-No.: CCL-1 
3.5.3. Animals 
C57BL/6 wt mice Charles River 
LTβR-/- mice Generated by Prof. K. Pfeffer, University of 
Duesseldorf; bred in individually ventilated 
cages (IVC) in the animal facility of the 
University of Regensburg; background 
C57BL/6 
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p55-TNFRI-/- Generated by Prof. K. Pfeffer, University of 
Duesseldorf 
p75-TNFRII-/- Generated by Dr. H. Bluethmann, 
Hoffmann-La Roche, Basel; 
both TNFR-/- strains are bred in the animal 
facility of the University of Regensburg; 
background C57BL/6 
3.6. Vectors 
Mouse thymus cDNA expression 
library/Uni ZAP II 
Prof. Schwaeble / University of Leicester 
pBluescript®II SK(-) phagemid Stratagene 
pCR®2.1-TOPO® Invitrogen 
pQE32 QIAGEN 
Uni-ZAP®XR Stratagene 
3.7. Primers  
(Metabion)  
LTBR-ZAP 3'SAL CCC CCG TCG ACT CAG AGG TCT TGG 
CAT CCT AG 
mLTßR-ECD(-D2)-KpnI CCC GGT ACC GCA AGT CTT GCA AAC 
CGT GTC TTG  G 
mLTßR-ECD(-D3)-KpnI CCC GGT ACC GCG GCA CTC GGC TTT 
CCG ATC G 
mLTßR-ECD(-D4)-KpnI CCC GGT ACC GGG GAC ACA GTT GAC 
GTC AGT ATC 
mLTßR-ECD-3'KpnI CCC GGT ACC TGG AGC TGC CTC CAC 
mLTßR-ECD-5'BamHI CCC GGA TCC TCA GCG GGC TTC TGG 
TGG CC 
mLTßR-ECD-5'BamHI-20aa CCC GGA TCC CTT GCT GGG ACC AGG 
ACA AGG 
mLTßR-ECD-5'BamHI-42aa CCC GGA TCC CTT GTC CCC CAG GCG 
AGT TTG TC 
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mLTßR-ECD-5'BamHI-61aa CCC GGA TCC CCC ATA ATT CCT ATA 
ATG AAC AC 
mLTßR-EcoRI-5' AAA CGA ATT CCA TGC GCC TGC CCC 
GGG CCT CC 
pQE-3'Seq (pQE32-sequencing) GAT GGA GTT CTG AGG TCA TTA CTG 
G  ("high") 
pQE-5'Seq (pQE32-sequencing) TAA TAG ATT CAA TTG TGA GCG GAT 
AAC  ("high") 
rev-pBS (pCR®2.1-TOPO® and 
pBluescript®II SK(-) sequencing) 
GGA AAC AGC TAT GAC CAT GAT  
("normal") 
uni-pBS (pCR®2.1-TOPO® and 
pBluescript®II SK(-) sequencing) 
TTG TAA AAC GAC GGC CAG TG  
("normal") 
  
3.8. Proteins 
 
hLTβR-ECD-Ig, S2-expressed Dr. P. Mueller, Institute of Immunology, 
Regensburg 
mLTβR-ECD-Ig, S2-expressed Dr. P. Mueller, Institute of Immunology, 
Regensburg 
mLTβR-whole ECD cloned by Agnes Fuetterer, University of 
Munich; Institute of Microbiology, Hygiene 
and Immunology; expressed in this work 
mLTβR-ECD-∆D4 this work 
mLTβR-ECD-∆D4,3 this work 
mLTβR-ECD-∆D4,3,2 this work 
mLTβR-ECD-(-61aa) this work 
mLTβR-ECD-(-42aa) this work 
mLTβR-ECD-(-20aa) this work 
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3.9. Constructs  
This work: 
Name Vector Insert Size (kb) 
Restriction-
sites 
Host-
strain Resistance 
mLTßR-cDNA 
clone 5 
pBS-
SK(-) 
mLTßR-
cDNA 
(Ex1-10) 3.0+1.256 EcoRI/SalI 
XL1-
MRF' Amp-200 
mLTßR-cDNA 
clone 1  
pCR2.1-
TOPO 
mLTßR-
cDNA 
(Ex1-10) 3.9+1.256 EcoRI/SalI 
TOP 
10 F'  
Amp-
50/Kan-50 
mLTßR-
cDNA-"library"
Uni 
ZAPII-
XR 
mLTßR-
cDNA 
(Ex1-10) 41+1.256 EcoRI/SalI 
XL1-
MRF' none 
mLTßR-ECD 
clone 1 pQE32  
mLTßR-
cDNA 
(Ex1-6) 3.4+0.621 EcoRI/KpnI M15 
Amp-100/ 
Kan-25 
mLTßR-ECD   
(-D2) clone1 pQE32  
mLTßR-
ECD 
(-D2,3,4) 3.4+0.194 BamHI/KpnI M15 
Amp-100/ 
Kan-25 
mLTßR-ECD   
(-D2) clone6 
pCR2.1-
TOPO 
mLTßR-
ECD 
(-D2,3,4) 3.9+0.194 BamHI/KpnI 
XL1-
MRF' 
Amp-100/ 
Kan-50 
mLTßR-ECD 
(-D3) clone 1 pQE32  
mLTßR-
ECD 
(-D3,4) 3.4+0.320 BamHI/KpnI M15 
Amp-100/ 
Kan-25 
mLTßR-ECD 
(-D3) clone 3 
pCR2.1-
TOPO 
mLTßR-
ECD 
(-D3,4) 3.9+0.320 BamHI/KpnI 
TOP 
10 F' 
Amp-50/ 
Kan-50 
mLTßR-ECD 
(-D4) clone 1 pQE32  
mLTßR-
ECD(-D4) 3.4+0.458 BamHI/KpnI M15 
Amp-100/ 
Kan-25 
mLTßR-ECD-
20aa clone2 pQE32  
mLTßR-
ECD-20aa 3.4+0.491 BamHI/KpnI M15 
Amp-100/ 
Kan-25 
mLTßR-ECD-
20aa clone 1 
pCR2.1-
TOPO 
mLTßR-
ECD-20aa 3.9+0.491 BamHI/KpnI 
XL1-
MRF' 
Amp-100/ 
Kan-50 
mLTßR-ECD-
42aa clone 1 pQE32  
mLTßR-
ECD-42aa 3.4+0.434 BamHI/KpnI M15 
Amp-100/ 
Kan-25 
mLTßR-ECD-
42aa clone 1 
pCR2.1-
TOPO 
mLTßR-
ECD-42aa 3.9+0.434 BamHI/KpnI 
XL1-
MRF' 
Amp-100/ 
Kan-50 
mLTßR-ECD-
61aa clone 4 pQE32  
mLTßR-
ECD-61aa 3.4+0.365 BamHI/KpnI M15 
Amp-100/ 
Kan-25 
mLTßR-ECD-
61aa clone 4 
pCR2.1-
TOPO 
mLTßR-
ECD-61aa 3.9+0.365 BamHI/KpnI 
XL1-
MRF' 
Amp-100/ 
Kan-50 
                                                                                                                      Material 
35 
3.10. Prepared buffers and solutions 
3.10.1. Working with cells; flow cytometry 
6x ACK-buffer 0.155 M NH4Cl   
 0.1 M KHCO3   
 0.1 mM EDTA pH8.0  
 pH should be 7.4; adjust with NaOH or HCl 
 sterilize by filtration; store at room temperature 
    
DNase free RNase A  100 mg Pancreatic RNase A  
 10 ml 0,01 M CH3COONa pH 5.2 
 disolve well; heat for 15min at 100°C 
 slowly cool down to room temperature 
 adjust pH with 0.1 volumes 1M Tris.Cl pH 7.4 
 store 1ml aliquots at -20°C  
    
PBS pH7.4 137 mM NaCl   
 2.7 mM KCl   
 8.1 mM Na2HPO4   
 1.5 mM KH2PO4   
    
Trypan blue  1.5 mg/ml Trypan blue  
 0.9 % NaCl   
    
    
3.10.2. Molecular biology techniques 
 
6x DNA Loading buffer III  0.25 % Bromphenolblue 
 0.25 % Xylene Cyanol FF 
 30 % Glycerol 
  
SM-buffer 100 mM NaCl 
 10 mM MgSO4.7H2O 
 50 mM Tris.Cl pH 7.5 
 autoclave; store at room temperature 
  
3M Sodiumacetate,  81,6 g CH3COONa.2H2O 
 pH 5.2 or pH 4.6 ad 400 ml H2O 
 adjust pH to 5.2 or 4.6 with glacial acetic acid 
 ad 500 ml H2O 
 autoclave; store at room temperature 
  
50x TAE-buffer 242 g/l Tris 
 57.1 ml/l Glacial acetic acid 
 100 ml/l 0.5M EDTA pH8.0 
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10x TBE-buffer 0.89 M Tris 
 0.89 M Boric acid 
 2 mM EDTA pH8.0 
  
TE pH8.0 10 mM Tris.Cl pH 8.0 
 1 mM EDTA pH 8.0 
 autoclave; store at room temperature 
 
3.10.3. Media and antibiotics 
 
LB-medium and plates 10 g/l Tryptone  
 5 g/l Yeast-extract 
 10 g/l NaCl  
 adjust pH to 7.0 with 5N NaOH 
 autoclave; store at room temperature 
 plates: add 1.5% agar-agar before autoclaving 
   
NZY-plates and top  5 g/l NaCl  
agarose 5 g/l Yeast-extract 
 10 g/l NZ-amine from bovine milk 
 2 g/l MgSO4.7H2O 
 0.7% Agarose or 1.5% agar-agar 
 adjust pH to ~7.5 with 10 N NaOH 
 autoclave; store at room temperature 
   
SOC medium 20 g Tryptone  
  5 g Yeast extract 
 0.5 g NaCl  
 disolve in 950ml H2O  
 10 ml 250 mM KCl 
 adjust pH to 7.0 with 5N NaOH 
 5 ml 2 M MgCl2 
 ad 1000 ml  H2O  
 autoclave; store at room temperature 
 right before use add glucose 
 to 20mM final concentration 
   
 stock solution working solution 
Ampicillin 200 mg/ml H2O 100 or 200µg/ml 
Kanamycin 50 mg/ml H2O 50 µg/ml 
 store in aliquots at -20°C 
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3.10.4. Expression and purification of His-tagged proteins 
 
all lysis, wash and elution buffers should be prepared right before use  
Lysis buffer A 100 mM NaH2PO4  
   10 mM Tris·Cl pH8.0 
        6 M Guanidiniumhydrochloride 
 0.1% Triton-X100 
 10% Glycerol  
 adjust pH to 8.0 with NaOH 
   
Wash buffer C 100 mM NaH2PO4  
   10 mM Tris·Cl pH8.0 
        8 M Urea  
 20 mM Imidazole  
 0.1% Triton-X100 
 10% Glycerol  
 adjust pH to 8.0 with NaOH 
   
Elution buffer D 100 mM NaH2PO4  
   10 mM Tris·Cl pH8.0 
        8 M Urea  
 10% Glycerol  
 adjust pH to 5.9 with HCl. 
   
Elution buffer E 100 mM NaH2PO4  
   10 mM Tris·Cl pH8.0 
        8 M Urea  
 10% Glycerol  
 adjust pH to 4.5 with HCl  
   
RIPA buffer  50 mM Tris.Cl pH7.4 
 150 mM NaCl  
 1 mM EDTA  
 0.25% Sodiumdesoxycholat 
 1% Triton-X100 
 1% NP40  
“complete” (Roche):        1 mM PMSF  
 each 1 µg/ml Aprotinine, Leupeptine and Pepstatine 
    1 mM Na3VO4  
      1 mM NaF  
 store in aliquots at -20°C 
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3.10.5. SDS-PAGE and western blots 
 
4x Laemmli loading buffer 250 mM Tris  
 4% SDS  
 40% Glycerol  
 4% β-Mercaptoethanol 
 pH should be ~6.8 
17% SDS PAGE   
- Stacking gel 4% PAA  
 125 mM Tris.Cl pH6.8  
 0.1 % SDS 
 0.1 % TEMED  
 0.1 % APS  
   
- Resolving gel 17% PAA  
 375 mM Tris.Cl pH8.8  
 0.1 % SDS 
 0.075 % TEMED  
 0.075 % APS  
   
5x SDS-PAGE running  120 mM Tris  
buffer 950 mM Glycine  
 0.5 % SDS  
    
Western blot buffer A 300 mM Tris  
 10% Methanol  
 adjust pH to 10.4  
   
Western blot buffer B 25 mM Tris  
 10% Methanol  
 adjust pH to 10.4  
   
Western blot buffer C 25 mM Tris  
 40 mM 6-amino-n-capronic acid    
 10% Methanol  
 adjust pH to 9.4  
   
TBS pH7.4 1.5 M NaCl  
 27 mM KCl  
 250 mM Tris 
Coomassie-Staining   
Staining 10% Glacial acetic acid 
 40% Methanol 
 0.2 % Coomassie brillant blue R250 
 filter before use 
   
Destaining 10% Glacial acetic acid 
 40% Methanol 
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Silver Staining   
Fixation 10% Glacial  acetic acid 
 40% Ethanol  
 
Sensitization 0.02% Sodiumthiosulfate 
  
Staining 0.2% Silvernitrate 
 0.02% Formaldehyde 
  
Developing 3% Sodiumcarbonate 
 0.05% Formaldehyde 
  
Stop solution 0.5% Glycine 
  
Solution for air-drying 5% Glycerol 
 35% Ethanol 
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4. Methods 
4.1. Working with thymocytes and splenocytes 
4.1.1. Isolation of thymocytes 
Thymi were taken from six to thirteen-week-old mice and strained through a 0.4µm 
mesh with 10ml 10% FCS/RPMI. Aggregates needed to be disrupted by pipetting 
up and down. The following washing step was performed in 40ml 10% FCS/RPMI 
and with centrifugation for 10 min at 200g. The clear supernatant was decanted 
and the cells were resuspended in 10ml 10% FCS/RPMI. A 1:10 dilution with 
5mg/ml Trypan blue was optimal for counting in a Neubauer chamber.  
Approximately 108 thymocytes were obtained in this way. All the cells needed for 
the following experiments were centrifuged again and resuspended in 5% 
FCS/PBS or 10% FCS/RPMI to a final concentration of 2x106 cells/ml.  
The whole procedure was performed on ice. 
4.1.2. Isolation of splenocytes 
Simultaneously, spleens were taken from the mice above. Any adhering adipose 
or connective tissue was cut off before opening the spleen on one end and 
carefully scraping the hematopoietic cells out of it. The cells were harvested in 
10ml 10% FCS/RPMI avoiding aggregates by vigorously pipetting up and down. In 
suspension the splenocytes were passed through a 0.4µm mesh and washed as 
described for the thymocytes. The pellet was resuspended in 1ml 10% FCS/PBS 
and erythrocytes were lysed with 4ml of 1x ACK buffer for 4 min with occasional 
shaking. Lysis was stopped with 5ml 10% FCS/RPMI and the cells were 
resuspended and passed through a mesh again. After an additional washing step 
the cells were resuspended in 10ml 10% FCS/RPMI and diluted 1:20 with Trypan 
blue for counting. 1-1.5x 108 splenocytes were obtained in this way. Like the 
thymocytes the splenocytes were adjusted to 2x106 cells/ml for further 
experiments after additional centrifuging.  
The whole procedure was performed on ice. 
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4.1.3. Cultivation of thymocytes 
Thymocytes were isolated under sterile conditions and distributed into a 48 well 
plate with 1x106 cells/500µl 10%FCS/RPMI/well.  
PMA (phorbol 12-myristate 13-acetate)/ionomycin (2µg/ml each) treatment was 
chosen as a positive control for thymocyte activation whereas the treatment with 
Rat-IgG2a (10µg/ml) served as a negative control for the treatment with the 
monoclonal rat anti mouse LTβR antibody 1C5 (10µg/ml). Rat-IgG2a and 1C5 were 
also crosslinked with a secondary antibody, goat anti rat-IgG (10µg/ml), in order to 
mimic oligomerization of ligands before binding their receptors.  
After 24 hours the cells were harvested, washed twice with ice-cold PBS and fixed 
in ice-cold 70% methanol for propidium iodide (PI) staining and flow cytometric 
analysis.  
For the IL2 ELISA the plates were centrifuged after 24h for 2 min at 200g and cell 
free supernatants were taken.  
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4.2. Flow cytometric analysis  
4.2.1. Determination of the DNA profile with propidium iodide 
The DNA content of  cells differs depending on the cell cycle. By staining the DNA 
for example with propidium iodide (PI) for further measurement by flow cytometry it 
is possible to conclude whether cells are resting or proliferating or maybe dying.  
Therefore 106 cells/tube were washed twice in ice-cold PBS and 
fixed/permeabilized in 1ml ice-cold 70% methanol for a minimum of one hour up to 
several days in the cold. After sufficient fixation the cells were washed twice with 
ice-cold PBS before destroying the RNA by adding  475µl of DNase-free RNase A 
(100µg/ml) for 20 min at 37°C. In order to stain the DNA 25µl PI (1mg/ml) were 
added. Immediately the cells were measured by flow cytometry on a FACSCalibur 
applying CellQuest software (both Becton Dickinson) with the following instrument 
settings: 
FSC E-1 log; SSC 340 log; FL3 485 lin 1.64; FL3A lin 1.43; FL3W lin 1.81; 
treshold FSC 52.  
30,000 events with ~300 events/sec were measured and finally analysed with 
WinMDI 2.8. (The Scripps Research Institute). 
4.2.2. Testing of all fractions of three different anti mLTβR antibodies 
Altogether four different monoclonal rat antibodies against the ECD of the mLTβR 
were generated (Hehlgans et al., 2003). Since then several people have worked 
with these antibodies and have purified a lot of different fractions from each clone. 
As first observations led to the conclusion that the different batches of each 
antibody had different avidities to its antigen it was necessary to test all of them for 
their binding behaviour. 
Therefore L929 cells, a mouse fibroblast cell line bearing the mLTβR on its 
surface, and, in the case of the cross-reacting antibody 1C5, thymocytes, were 
chosen for testing all fractions of the three monoclonal antibodies 1C5, 12H11 and 
5G11b. The fourth antibody 5D12a2 was of minor interest at this point. All antibody 
concentrations were determined with the DC Protein Assay, a modified Lowry, 
according to the manufacturer’s protocol. 
 
L929 cells were harvested by mild trypsinisation, washed, counted and adjusted to 
1x106 cells/ml/tube. Thymocytes were prepared as described above and adjusted 
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to the same concentration. After centrifugation for 10 min at 200g the pellets were 
resuspended in 100µl of blocking solution containing 1% normal rabbit serum in 
10% FCS/PBS and incubated for 20min on ice. The blocking solution was 
removed before the addition of the different fractions of the primary antibodies 
1C5, 12H11 or 5G11b (10µg/ml in 10% FCS/PBS) or the isotype control, rat IgG2a 
(10µg/ml) for one hour on ice. In the case there were no purified antibodies 
available but rather supernatants, 100µl of the supernatants were taken as the 
primary antibody. Three washing steps followed, each included the addition of 1ml 
5% FCS/PBS, mixing and centrifuging for 10min at 200g. For the detection of the 
bound primary antibodies, 100µl of the secondary antibody,  rabbit anti rat Ig, 
FITC-labeled, with a concentration of 4µg/ml was added for an additional hour on 
ice followed by three washing steps as above. The cells were resuspended in 
500µl 5% FCS/PBS after the last washing step and measured as soon as possible 
by  flow cytometry. 
Instrument settings for the FACSCalibur: 
FSC E-1 log; SSC 260 log; FL1 750 (thymocytes) or 475 (L929);  treshold FSC 52. 
50,000 events with ~1000 events/sec were measured with CellQuest and finally 
analysed with WinMDI 2.8. 
For further flow cytometric analysis and western blots the antibodies which 
showed the strongest shift were chosen (see chapter 3.3.1).  
4.2.3. Four colour flow cytometric analysis 
The method chosen to differentiate the thymocytes and the splenocytes 
expressing the unknown protein was a simultaneous staining of the cells with four 
different antibodies, each labeled with another dye, and analysis by flow 
cytometry. The prerequisite for a multicoclor analysis is the optimal concentration 
of each antibody and the right compensation of each colour/channel at the flow 
cytometer. Therefore it was necessary first to perform single color staining with 
each antibody.  
Thymocytes were prepared as described above. 2x106 cells per tube were 
incubated on ice for 15min with 50µl of rat anti mouse Fcγ RIII/II, 10µg/ml in 10% 
FCS/PBS, to block any unspecific binding sites. The labeled primary antibodies 
were added in a 50µl volume leading to a final concentration of 1.0, 2.5, 5.0 and 
10.0µg/ml in 10% FCS/PBS. As primary antibodies the following clones were 
chosen, all generated in rats except anti-CD69 (armenian hamster): 
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Antibody-Colour Clone Channel 
1C5-FITC F3 FL1 
Anti-CD3-PE 17A2 FL2 
Anti-CD4-PE RM4-5 FL2 
Anti-CD8a-APC 53-6.7 FL4 
Anti-CD45R/B220-PE RA3-6B2 FL2 
Anti-CD69-PerCP-CY5.5 H1.2F3 FL3 
Anti-CD117-PE ack45 FL2 
 
The individual isotype controls were used at 5µg/ml. After one hour of incubation 
on ice the cells were washed three times as described above and resuspended in 
500µl 5% FCS/PBS. 
Cells were measured at the FACSCalibur with CellQuest and the following 
settings: 
FSC E-1 log; SSC 260 log; FL1 750 log; FL2 690 log; FL3 937 log; FL4 850 log; 
threshold FSC 230. 
20,000 events in the lymphocyte gate were counted with ~500 events/sec.  
To obtain the optimal concentration for each antibody the mean fluorescence 
intensities were plotted against the applied concentrations. The concentration 
leading to the last point before the curve reached the plateau was chosen as the 
optimal concentration for four colour staining. The optimal concentration for each 
antibody was 5µg/ml, except for anti-CD117 which should be used with 10µg/ml.  
With these optimised concentrations the compensation for each channel at the 
flow cytometer was performed with thymocytes and splenocytes.  
The staining protocol was the same as above. This time 30,000 events were 
counted in the lymphocyte gate with the following instrument settings: 
FSC E00 lin 1.8; SSC 447 lin 1.49; FL1 750 log; FL2 722 log; FL3 937 log; FL4 
850 log; threshold FSC 52. The linear scale for the forward and the sideward 
scatter was chosen because it was more convenient for distinguishing the 
lymphocytes from the other cells especially in the spleen. FL2 needed a little 
correction in the PMT voltage.  
Viewing the neighbouring channels on parallel dot plots provided the chance to 
compensate fluorescence overspills.  
                                                                                                                     Methods 
45 
The following compensations were determined: 
 
FL1-  2.0% FL2 
FL2-17.4% FL1 
FL2-  2.1% FL3 
FL3-12.5% FL2 
FL3-  2.4% FL4 
FL4-  2.5% FL3 
 
In the thymus 1C5-FITC in FL1 needed a stronger compensation (2.5%) against 
CD45R/B220-PE and CD117-PE in FL2. 
 
With these optimized concentrations, compensations and instrument settings, four 
color analysis could finally be performed following the protocol described above. 
All four antibodies were added to the cells at the same time with these 
combinations: 
1C5-FITC + CD69-PerCP-CY5.5 + CD8a-APC + either CD3-PE, CD4-PE, 
CD45R/B220-PE or CD117-PE. The isotype control was a combination of rat-
IgG2a-FITC, -PE, -APC and armenian hamster-IgG1-PerCP-CY5.5, each with 
5µg/ml. 
In order to get enough cells for analysis even in the subpopulations with very few 
cells, 100,000 cells were measured in the lymphocyte gate. This meant to 
measuring ~ 140,000 thymocytes and 220,000 splenocytes.  
To exclude dead cells PI was added to the autofluorescence control. PI stains 
necrotic and late apoptotic cells but not living cells if they are not 
fixed/permeabilized. There were only up to five percent dead cells equally 
distributed over all populations so they could be neglected for the analysis in 
WinMDI 2.8.  
Regions and quadrants separating positive from negative cells were set according 
to the autofluorescence, isotype-controls and single-staining patterns.  
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4.3. Molecular biology techniques 
4.3.1. Cloning of the expression constructs 
4.3.1.1. PCR 
Saiki et al., 1985 
For the epitope mapping it was necessary to clone the truncated extracellular 
domain (ECD)-cDNAs of the mLTβR into a prokaryotic expression vector. In a first 
step these cDNAs needed to be amplified via PCR with the addition of restriction 
sites for the following ligation into a vector. The cDNA of the whole ECD, 
previously cloned into pcDNA3, was taken as the template for all PCRs. The 
truncation of the ECD starting from the 3’ end and deleting the fourth (∆D4), the 
third and the fourth (∆D4,3) or the second, third and fourth cysteine rich domains 
(∆D4,3,2) was performed with one 5’ primer (mLTßR-ECD-5'BamHI) and three 
different 3’ primers (mLTßR-ECD(-D4)-KpnI or mLTßR-ECD(-D3)-KpnI or mLTßR-
ECD(-D2)-KpnI). For the truncation of the ECD from the 5’ end, in order to delete 
20 amino acids (-20aa), 39 amino acids (-42aa) or 61amino acids (-61aa), one 
common 3’ primer (mLTßR-ECD-3'KpnI) and three different 5’ primers (mLTßR-
ECD-5'BamHI-20aa or mLTßR-ECD-5'BamHI-42aa or mLTßR-ECD-5'BamHI-
61aa) were combined. The cDNAs were amplified in a 50µl volume under the 
following conditions: 
 
 Final concentration 
Template DNA: 300ng 
Reaction buffer: 1x, incl. 1.5mM Mg2+ 
5’ primer: 1.0µM 
3’ primer: 1.0µM 
dNTPs: 0.2mM each 
Taq polymerase: 0.1U/µl 
 
Cycling conditions:  
2min 96°C ? 45 cycles :  30sec 96°C    
                                          30sec 65°C (5’truncation)  or  68°C (3’truncation) 
                                            1min 72°C ?  30min 72°C 
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Water was substituted for the template DNA in the case of a negative control for 
each reaction.  
To check the PCRs, 5µl of each reaction product and its water control were loaded 
on a 1% agarose/1xTAE gel and separated at 10V/cm according to their size. DNA 
was visible after ethidiumbromide staining and exposure to UV light (254nm). 
4.3.1.2. Purification of DNA from PAA gels 
The PCR products were purified from a PAA gel according to Sambrook’s and 
Russells’ (2001) suggestion for DNAs with less than 1000 bp. For the purification 
of the PCR products the residual 45µl were mixed with 15µl 6x loading buffer and  
loaded on a 5% PAA/1xTBE gel, separated with constant current of 30mA and cut 
out under UV light control (366nm) after ethidiumbromide staining. The cut 
fragments were ground with a pestle and vigorously shaken for 2h in 1ml 0.1x TE 
buffer for eluting the DNA from the PAA. The volume was reduced with butanol to 
~400µl for further precipitation of the DNA with 1/10 volumes of 3M 
sodiumacetate, pH5.2 and 2 volumes of 100% ethanol. After centrifuging for 30min 
the pellets were washed with 500µl 70% ethanol, dried and disolved in 10µl water.  
In order to check the purity and the concentration of the PCR products 2µl of the 
purified DNA were separated on a 1% agarose gel again.  
4.3.1.3. Cloning into pCR®2.1-TOPO® 
An intermediary step with cloning the PCR products into pCR®2.1-TOPO® with the 
TOPO TA Cloning® kit before insertion into the expression vector was chosen 
because the restriction enzymes do not cut right at the beginning of the PCR 
products depending on the secondary structure given by the DNA sequence. PCR 
products can be cloned directly into pCR®2.1-TOPO®  using the property of the 
Taq polymerase of adding an adenine to the 3’ end of each product with its 
terminal transferase activity. The pCR®2.1-TOPO®  vector carries an overhanging 
thymidine at its 5’ end. Cloning was performed according to the manufacturer’s 
instructions with some changes.  
The DNA concentration of the purified PCR products was estimated according to 
the molecular weight standard XIV. Approximately 2.5-6.0ng DNA, depending on 
the length of the PCR product, were added to 10ng of pCR®2.1-TOPO®  vector 
DNA together with the recommended salt solution (final concentrations: 0.2M 
NaCl, 6mM MgCl2) in a final volume of 6µl. After 30min at room temperature the 
mixture was cooled down on ice and 200µl of competent XL1-Blue MRF’ or One 
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Shot®TOP10F’ E.coli instead of One Shot®TOP10 E.coli were added. XL1-Blue 
MRF’ and One Shot®TOP10F’ were chosen because the smallest construct 
seemed to be toxic. Therefore competent cells with the lac repressor (lacIq gene) 
were needed to avoid any expression of the construct during the cloning 
procedure. One Shot®TOP10F’ were bought from Invitrogen whereas XL1-Blue 
MRF’ were made competent with CaCl2, MnCl2 and CoCl2 according to Hanahan, 
1983. After incubation on ice for 30min the bacteria were heat shocked for 90sec 
at 42°C to further open their membrane for an easier import of the plasmid and 
immediately cooled down on ice again. With the addition of three volumes SOC 
medium and incubation for 1h at 37°C with gentle shaking the bacteria started 
expressing the resistance gene which is needed for the selection of the plasmid 
carrying cells. For this selection the transformed bacteria were spread on LB 
plates with each 50µg/ml ampicillin and kanamycin (One Shot®TOP10F’) or 
100µg/ml ampicillin and 50µg/ml kanamycin (XL1-Blue MRF’) and let grow 
overnight at 37°C. The next day five colonies per clone were inoculated into 3ml 
LB medium containing ampicillin and kanamycin and again let grow overnight at 
37°C. 
4.3.1.4. Small scale plasmid DNA preparation 
Plasmid DNA was extracted from the whole 3ml overnight culture with the Wizard® 
Plus Minipreps DNA Purification System from Promega according to the 
manufacturer’s instruction. DNA was eluted from the column with 50µl 10mM 
Tris.Cl pH8.0 instead of 100µl water. Five µl of each plasmid were taken for a 
restriction enzyme digest to check whether the plasmids were the right ones. In 
the pCR®2.1-TOPO®  vector two EcoRI sites 5’ and 3’ flanking the cloning region 
allow to cut out the insert. As there are no BamHI or KpnI sites in pCR®2.1-TOPO®  
it was also possible to check the plasmids for the added restriction sites with these 
two enzymes. The restriction digests were performed in a total volume of 10µl with 
1x buffer and 5 units of each enzyme for 2h at 37°C. After the separation on a 1% 
agarose gel with 10V/cm all clones with the right restriction patterns were 
sequenced before further subcloning into the expression vector.  
4.3.1.5. Sequencing 
Sequencing was performed with the ABI Prism® BigDyeTM Terminator Cycle 
Sequencing Ready Reaction Kit from Applied Biosystems which combines the 
original didesoxynucleotide sequencing technique Sanger established in 1977 with 
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the use of fluorescent labeled terminators and the PCR. The concentration of the 
plasmid DNA was estimated from the gel according to the molecular weight 
standards X and XIV or, in case of large scale prepared DNA, measured at 260nm 
in a photometer. 700ng of plasmid DNA were added to 6.4pmol sequencing primer 
and 8µl premix from the kit. The volume was filled with water to 20µl. Depending 
on the G/C content of the primer one of the three established sequencing-
programs was let run.  
 
"normal": 15sec 96°C "low": 15sec 96°C "high": 15sec 96°C 
 15sec 55°C 15sec 50°C 15sec 60°C 
 4min 60°C 4min 60°C 4min 62°C 
 
Each cycle was repeated 35 times. The sequencing reactions were purified by the 
addition of 1/10 volume of 3M sodiumacetate pH4.6 and 2 volumes of 100% 
ethanol. After precipitation at room temperature for 20min in the dark the samples 
were centrifuged for 30min at 16000g, washed with 500µl 70% ethanol, dried and 
dissolved in 25µl template suppression reagent (TSR) for the ABI310 Genetic 
Analyzer or 12µl Hi-Di Formamide, Genetic Analysis Grade for the ABI3100-Avant 
Genetic Analyzer. Both machines separate the sequencing products on a polymer 
in a capillary. The received sequence data were compared with the published 
mLTβR sequence, accession number NM_010736. Those clones without any 
mutation were used for further work and stored long term as a 25% glycerol stock 
at -80°C. 
4.3.1.6. Cloning into the expression vector pQE32 
The pQE32 vector from QIAGEN was chosen for expressing the constructs 
because it was also used for generating the original clone expressing the whole 
ECD of mLTβR, which was used for immunization. This vector adds a 6x His tag at 
the amino terminus of each expressed protein. Such a 6x His tag can be used for 
further enrichment or purification and detection of the expressed proteins. pQE32 
consists of a phage T5 promoter which is recognized by the E. coli RNA 
polymerase. The host strain M15[pREP4] expresses a lac repressor from the lacIq 
gene on its pREP4 plasmid. The lac repressor blocks the  two lac operator 
sequences in the vector until IPTG is added to induce the expression of the 
inserted cDNA. With this system cDNAs which would be transcribed and 
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translated into toxic proteins can also be cloned. Transformed bacteria are 
resistant to 100µg/ml ampicillin (pQE32) and 25µg/ml kanamycin (pREP4).  
4.3.1.6.1. Preparation of the vector 
pQE32-DNA was bought from QIAGEN, transformed into E.coli and prepared in a 
large scale for further applications. As a BamHI- and a KpnI-site were added to the 
truncated ECDs during PCR for further cloning, the vector needed to be cut with 
these two enzymes.  To avoid any religation of the vector caused by insufficient 
digestion it was also dephosphorylated. For the digestion with BamHI and KpnI 
15µg vector DNA were cut overnight at 37°C in 100µl of the following reaction 
mixture: 1x buffer A + 1mg/ml BSA + 0.5u/µl of each enzyme. 
The digested DNA was separated on a 1% agarose gel. The fragment 
representing the digested vector DNA was cut out under UV-light control (366nm) 
and purified with the QIAEXII Gel Extraction Kit from QIAGEN according to the 
manufacturer’s instructions.  After elution of the DNA with 2x 50µl 10mM Tris.Cl 
ph8.0 an additional purification step was performed. Residual proteins were 
extracted once with phenol/chloroform and once with chloroform. The DNA was 
precipitated as described in 4.3.1.2 and resuspended in 20µl water.  
The dephosphorylation of the digested and purified DNA was performed in a 100µl 
reaction mixture of the following composition: 1x SAP buffer + 0.02u/µl shrimp 
alkaline phosphatase + 20µl purified vector DNA. After 90min at 37°C the 
dephosphorylation was stopped for 15min at 65°C. A double phenol/chloroform 
and chloroform extraction and  a precipitation were performed as described above. 
After disolving in 20µl water 2µl of the DNA were checked on a 1% agarose gel for 
quality and quantity.  
4.3.1.6.2. Preparation of the inserts 
For cloning the truncated ECDs from pCR®2.1-TOPO®  into pQE32, the TOPO® 
clones were cut overnight with BamHI/KpnI. For this process 35µl DNA from the 
small scale preparation were incubated with 1x buffer A + 1mg/ml BSA + 0.8u/µl of 
each enzyme in a total volume of 75µl. The fragments were separated on a 5% 
PAA gel and purified as described in 4.3.1.2. Four µl of the purified 10µl were 
separated on a 1% agarose gel to estimate the DNA concentration for the 
following ligation. 
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4.3.1.6.3. Ligation of the truncated ECDs into pQE32 
For the ligation a molar ratio of vector:insert of 1:3-5 and a volume as small as 
possible were chosen according to Sambrook and Russell, 2001.  Before ligating 
both, vector and insert were precipitated together in a total volume of 100µl.  
The dried pellet was disolved in 8µl water before adding 1x ligation buffer and 
400U T4 DNA ligase in a total volume of 10µl. Ligation ran over night at 16°C.  
4.3.1.6.4. Transformation ito M15[pREP4] E. coli 
M15 E. coli were made competent  with CaCl2, MnCl2 and CoCl2 according to 
Hanahan, 1983. The whole ligation reaction was added to 200µl of competent M15 
on ice. Transformation followed the same procedure used for TOPO TA® cloning 
and clones were selected using 100µg/ml ampicillin and 25µg/ml kanamycin.  
Plasmid DNAs of the pQE32 clones were prepared in a small scale and checked 
as described above for the TOPO® clones with restriction enzymes and 
sequencing. For long term storage large scale preparations were performed with 
the QIAGEN Plasmid Maxi Kit according to the manufacturer’s instructions. All 
bacterial clones with the right restriction pattern and a sequence in frame without 
any mistakes were stored as 25% glycerol stocks at -80°C. 
4.3.2. Screening of a mouse thymus cDNA expression library 
A mouse thymus cDNA expression library was available as a gift from Prof. 
Schwaeble, University of Leicester. Poly (A)+-mRNA was extracted from thymi of 
three newborn mice, transcribed into cDNA and cloned into λZAPII by scinet. A 
first round of screening was performed according to the instructions of Stratagene 
with some variations. 
The maltose receptors of XL1MRF’ E.coli were induced overnight with 0.2% 
maltose and 10mM MgSO4 in 50ml LB medium for uptaking the phages. After 
intensive washing with 10mM MgSO4 to get rid of the maltose and adjusting the 
bacteria to an optical density OD600=0.6 (~5x108/ml), a serial ten fold dilution of the 
phages with SM buffer, starting with estimated 103 pfu (plaque forming unit) per 
plate, was performed in order to find the actual titer of the library. Infected bacteria 
(200µl) were incubated for 15min at 37°C before being mixed with 3ml NZY 0.7% 
top agarose (48°C), poured on prewarmed 96mm NZY plates and let grow 
overnight at 37°C. In a first round of screening 20 plates (132mm) were prepared 
each with calculated 8x103 phages in 600µl induced XL1MRF’ and 8ml top 
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agarose. After five hours at 42°C the first small plaques were visible. For the 
induction of the expression nitrocellulose filters, soaked in 20mM IPTG, were laid 
on the plaques for 4h at 37°C. These filters, marked for the right orientation, were 
carefully lifted after the induction and washed in 0.05% Tween-TBS for 5min and 
for 30min with gentle shaking. For blocking of unspecific binding the filters were 
incubated over night with 1% low fat dry milk powder/0.05% Tween-TBS at 8°C. 
To avoid false positive plaques the plates were screened a second time. Again the 
plaques were covered with filters for 6h at 37°C. The filters were processed like 
the first ones. 
The prerequisite an antibody which is used for library screens has to fulfill is a  
sensitivity high enough to detect down to 50-100pg of its antigen. Therefore dot 
blots were performed titrating the S2-expressed mLTβR-Ig-V5 fusion protein from 
100ng to 16pg. These dot blots were incubated with the cross-reacting antibody 
1C5 in concentrations of 2µg/ml and 3µg/ml. With the detection system alkaline 
phosphatase-NBT/BCIP amounts of protein down to 160pg with both antibody 
concentrations were visible. Controls with another mLTβR antibody, 5G11b, with 
anti-V5 or rat-IgG2a instead of 1C5 and with the prokaryotically expressed mLTβR-
ECD proved the sensitivity and specificity of this system. 
To detect phages expressing the unknown protein the filters were incubated with 
1C5 (2µg/ml) in 1% low fat dry milk powder/0.05% Tween-TBS for 3h at room 
temperature. After three intensive washing steps, each lasting 15min, the filters 
were incubated with the detection antibody goat anti rat IgG-alkaline phosphatase 
coupled (AP) (1.2µg/ml total protein) for 90min at room temperature followed by 
intensive washing again. NBT/BCIP is a  substrate for AP which turns from white 
to violet and would make the positive plaques on the filter visible. Incubation with 
the substrate Sigma FASTTM BCIP/NBT (1 tablet/10ml water) was performed over 
night although first signals were seen after 30min on the dot blots. As there were 
no positive plaques visible this screen needs to be repeated with a minimum 106 
pfu. 
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4.3.3. Preparation of a cDNA library only expressing the mLTβR 
The screening of an expression library is a useful tool in order to find a protein with 
which an antibody cross-reacts. As there was no positive control for checking the 
technique itself, it was decided to prepare a library only expressing the mLTβR. 
Therefore the whole cDNA of the mLTβR was amplified via PCR as described in 
4.3.1.1. Depending on the G/C content of the primers the annealing temperature 
needed to be changed to 62°C. With the primers mLTβR-EcoRI-5’ and  LTβR-
ZAP-3’Sal an EcoRI site was added at the 5’ end and a SalI site at the 3’ end for 
further cloning into Uni-ZAP® XR, the arms of λZAPII, the phage in which the 
mouse thymus cDNA library also was cloned. The PCRs were purified and cloned 
into pCR®2.1-TOPO® as described above. The TOPO® clones with the right 
restriction patterns and a sequence with no flaws were subcloned into 
pBluescript®II SK(-) phagemid (pBS SK(-)) as a control for the right orientation 
because pBS-SK (-) is a part of the later used phage Uni-ZAP® XR. The pBS-SK(-) 
was bought from Stratagene and prepared like the pQE32 vector before it was 
used for ligation. Ligation into the EcoRI/XhoI-cut pBS-SK(-) and transformation 
into XL1MRF’ were performed as described above in 4.3.1.6.3 and 4.3.1.6.4. 
Clones with the right restriction patterns, orientation and frame were prepared for 
long term storage in a large scale and as a glycerol stock and used for further 
subcloning into the phage arms Uni-ZAP® XR. Before ligation into the phage arms, 
15µg of the pBS-SK(-) containing the whole mLTβR-cDNA were cut with 
EcoRI/SalI and purified as described above in 4.3.1.2. Overhanging ends after SalI 
digest are compatible with XhoI sites. Ligation of the mLTβR-EcoRI/SalI fragment 
into the phage arms Uni-ZAP® XR was performed in a 5µl volume containing 1x 
ligation buffer, 200U T4 DNA ligase, ~30ng of the fragment and 1µg of the bought 
phage arms at 16°C overnight. Equal molar ratios of insert and phage arms were 
suggested to avoid multiple inserts. Control ligations with or without control 
plasmid DNA were performed in the same way. After the ligation the phages were 
packed  with the use of the Gigapack® III Gold Packaging Extract from Stratagene. 
The packaging of the phages and the induction of the maltose receptors of 
XL1MRF’ for uptaking the packed phages were performed according to the 
manufacturer’s instructions (the latter described in detail in 4.3.2). The titer of the 
produced library was determined by plating the phages in NZY top agarose on 
NZY plates without any antibiotics. For long term storage at  -80°C the library was 
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amplified and the titer was checked again.  Amplification was performed by plating 
20x 5.5x104 pfu for 7h at 37°C. Eight ml SM buffer were added per plate and 
shaken for 16h at 8°C. Phages and part of the bacteria were harvested in the SM 
buffer and incubated with 5% chloroform for 15min at room temperature in order to 
lyse the bacteria. After centrifuging for 10min at 500g the supernatants were 
combined. Three tubes were taken for long term storage at -80°C in 7% DMSO. 
The remaining supernatants were stored at 8°C after adding 0.3% chloroform. 
Uni-ZAP® XR phages have the advantage of enabling the extraction of the cDNA 
of a positive plaque directly as a plasmid with a technique called “in vivo excision”. 
Getting a plasmid containing the whole mLTβR-cDNA was a good quality control. 
Therefore another E.coli strain, SOLRTM, was induced and infected with 5x108 
phages together with 107 pfu of the Ex-Assist® interference-resistant helper phage. 
According to the manufacturer’s instructions, 200µl of the final bacteria suspension 
were plated on LB plates with 50µg/ml ampicillin. After an overnight incubation at 
37°C colonies appeared, were inoculated and their DNA was extracted on a small 
scale as described above in 4.3.1.4. Checking for the restriction pattern and the 
sequence led to the conclusion that the library was fine. The last control will be the 
expression screen with the cross-reacting antibody 1C5, with the mLTβR-specific 
antibody 5G11b and with rat-IgG2a as a negative control. 
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4.4. Protein chemistry techniques 
4.4.1. IL2 ELISA 
Activated T cells secrete IL2 in order to activate their own IL2 receptor for further 
proliferation. The IL2 ELISA “Duo Set” from R&D was used for measuring the 
supernatants of cultivated thymocytes after 24h of stimulation with PMA/ionomycin 
or the cross-reacting antibody 1C5. The procedure was performed in triplicates of 
10% of the supernatants according to the manufacturer’s protocol. The IL2 
antibody complexes were detected with streptavidin-horseradish peroxidase 
(HRP) and its substrate ABTS followed by measurement at 405nm in an ELISA 
reader. Optical densities of the supernatants were compared to those of a serial 
two fold diluted standard.  
4.4.2. Protein assay 
The concentrations of the purified anti mLTβR-antibody fractions were determined 
by measuring their optical density at 280nm and by the DC Protein Assay from 
Biorad, a modified Lowry assay. According to the manufacturer’s instructions a 
serial two fold diluted albumin standard or the antibodies were mixed with reagent 
A and B and measured at 650nm in an ELISA reader after 15min. 
4.4.3. Prokaryotic expression and enrichment of His tagged proteins 
All truncated ECDs of mLTβR were cloned into the expression vector pQE32 and 
M15[pREP4] E. coli from QIAGEN. For the enrichment of His tagged proteins Ni-
NTA technology was applied. Nitrilotriacetic acid (NTA) occupies four of the six 
ligand binding sites of the nickel ion leaving two sites free to interact with the 6x 
His tag. The Ni-NTA complex, coupled to Sepharose® CL-6B, called “Ni-NTA 
Agarose” (QIAGEN), was chosen for the enrichment of the expressed truncated 
constructs, performed according to a procedure which is based on the 
manufacturer’s, Frenzel et al 2003 and Harrison 1991.  
Three colonies of each construct, fresh spread from glycerol stocks on selection 
plates, were inoculated in 10ml LB medium with ampicillin/kanamycin. After being 
gently shaken overnight at 30°C, 2.5ml of each culture were transferred into 50ml 
LB medium with ampicillin/kanamycin. Approximately 90min later the cultures 
reached an OD600 of 0.5 which was optimal for the expression induction. Therefore 
1mM IPTG was added for 1h at 30°C.  Expression was stopped on ice for 10min 
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before the cells were centrifuged at 3000g for 20min at 4°C. The pellets were 
resuspended in 5ml lysis buffer A and shaken for 1-2h at 8°C or until the 
suspensions became clear.  After centrifuging for 40min the supernatants were 
transferred to a 15ml tube and incubated with 1ml of Ni-NTA Agarose overnight at 
8°C with rotation. To get rid of all non bound proteins the suspension was 
centrifuged for 5min at 3000g. The collected Agarose with the bound His tagged 
proteins was washed twice with wash buffer B and finally transferred to 1.5ml 
cups. Elution of the proteins from the Agarose was performed with 2x 300µl elution 
buffer D and 2x 300µl elution buffer E. To separate the proteins on a SDS-PAGE 
200µl 4x Laemmli buffer were added to the eluted proteins and 175µl to the 
residual Agarose. 
4.4.4. Preparation of the mLTβR from L929 cells for western blots 
Approximately 2x108 L929 cells were trypsinized, centrifuged for 10min at 200g 
and lysed in 6ml RIPA buffer. After one hour of shaking at room temperature the 
cell debris was centrifuged for 20min at 3000g. The supernatant was stored at -
20°C and the pellet was resuspended in 100µl 4x Laemmli buffer, denatured for 
5min at 95°C and subjected to an SDS-PAGE. 
4.4.5. SDS-PAGE  
Laemmli, 1970 
SDS binds proteins in a constant charge to mass ratio which allows the separation 
of the proteins in an electric field approximately according to their molecular 
weight. To separate the truncated proteins with a size between 9kD and 30kD 
17% SDS-PAA gels were let run in 1x SDS-PAGE running buffer with a constant 
current of 30mA in the stacking gel and 40mA in the resolving gel. The sizes of the 
fragments were  compared with the broad range molecular weight standard of 
Biorad (20µl). Either 40µl of the residual resin or 100µl of the eluted proteins each 
in 1x Laemmli buffer were loaded after a denaturing step of 5min at 95°C and 
cooling down.  
4.4.6. Silver staining of the proteins after SDS-PAGE 
Proteins can be made visible after electrophoresis either for example with 
Coomassie or with silver. In the case of the truncated proteins the more sensitive 
silver staining was the method of choice because of the small amounts of 
extracted proteins. The staining procedure followed a procedure published by 
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Blum et al 1987, adapted by Prof. Goerg/University of Weihenstephan (personal 
communication).  
PAA gels were fixed in 10% acetic acid/40% ethanol overnight at 8°C with gentle 
shaking. Three washing steps for 20min each were performed at room 
temperature, twice with 30% ethanol and once with water. Gels were sensitized 
with 0.02% sodiumthiosulfate and washed three times for 20sec with water. 
Staining was performed in a filtered 0.2% silvernitrate/0.02% formaldehyde 
solution at 8°C for 20min. Three 20sec washing steps with water followed before 
the silver grains were developed in 3% sodiumcarbonat/0.05% formaldehyde at 
room temperature until the right intensity appeared. The gels were washed three 
times in water for 20 sec and the color development was stopped with 0.5% 
glycine for 10min at room temperature. Gels were finally washed in water for three 
10min periods and scanned for documentation. In order to store the gels they were 
soaked in 5% glycerol/35% ethanol for 1h, wrapped with cellophane also soaked 
in the mixture and fixed in an easy breeze gel drying frame for air drying overnight 
at room temperature.  
4.4.7. Western blots 
Towbin et al., 1979 
Proteins were transferred from a gel to a PVDF membrane by a semi dry blotting 
system. The manufacturers of the blot machine (Biometra) and of the PVDF 
membrane Immobilon P (Millipore) suggest a three buffer system. Accordingly, 
each three pieces of 3MM Chr chromatography paper the same size as the gel 
were soaked in blot buffer A, B or C. The gel was washed and fixed for 15min in 
blot buffer C and the membrane needed to be rehydrated in methanol for 15sec, 
washed in water for 2min and prepared for the transfer for 5min in blot buffer B. 
Three papers from blot buffer A were laid on the anode without any air bubbles in 
between. Three papers from blot buffer B were laid down before the membrane 
was added. The gel was placed on the membrane and marked for later 
identification and orientation. Three papers from blot buffer C provided the contact 
to the cathode. The transfer ran at 0.4mA/cm2 for 2h. The current was half of the 
normally used current and the transfer time was doubled due to the small 
molecular weight of the proteins.  
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4.4.8. Immunodetection of proteins on a membrane with enhanced        
chemiluminiscence ECL 
Proteins were detected on the membranes with indirect immunoperoxidase 
technique. For this the membranes were incubated overnight at 8°C with a 
blocking solution containing 1% low fat dry milk powder in 0.05% Tween-TBS.  In 
the case of the polyclonal serum an additional blocking step with 0.1% normal goat 
serum in blocking solution was performed for 1h. The first antibody, specific for the 
protein, or the isotype control Ig, were added for 2h at room temperature with a 
concentration of 2µg/ml in blocking solution. The polyclonal serum was used in a 
1:10000 dilution in blocking solution. If the antibody anti-RGS-His4 (mouse IgG1) 
was used, blocking was performed in 3% BSA-fractionV/0.05% Tween-TBS and 
the antibody was diluted to 0.1µg/ml in BSA blocking solution. After three 10min 
washing steps with 0.05% Tween/TBS a secondary antibody, detecting the isotype 
of the first antibody (i.e. goat anti rat IgG, goat anti rabbit Ig, or goat anti mouse 
IgG), coupled with horseradish-peroxidase (HRP), was added for another hour at 
room temperature, diluted 1:1000 in blocking solution(~0.5µg/ml total protein). 
Three intensive washing steps were needed again before adding the substrate. 
The substrate is a 1+1 mixture of solution A and B from Nowa. HRP oxidizes 
luminol (B) in the presence of hydrogen peroxide (A) and alkaline pH. Oxidized 
and activated luminol emitts light for a short time. After being rinsed for ~1min with 
the substrate solutions, the blots were placed between two foils in a radiography 
cassette and exposed to a special autoradiography film (Hyperfilm) for 15sec to 
30min depending on the signal intensities.  
4.4.9. Coomassie staining of the membrane 
In order to see which proteins the signals belong to, the membranes were stained 
with Coomassie. For this the membranes were soaked in 0.2% Coomassie Brillant 
Blue R250 for a few seconds and destained with 10% acetic acid/40% methanol. 
Before drying the membranes they were washed intensively with water to get rid of 
the acetic acid.  
                                                                                                                       Results 
59 
5. Results  
5.1. Biological function of the unknown protein 
In earlier studies BFS1-cells, a mouse fibrosarcoma cell line, showed MIP2-
release as a sign for activation after treatment with the antibody 1C5 (Muller, 
2001). Therefore it was interesting to find out whether thymocytes also can be 
activated with 1C5.  
To study this question thymocytes from C57Bl/6-wt and LTβR-deficient (LTβR-/-) 
mice were treated for 24h with PMA/ionomycin as a positive control for activation 
or with the antibody 1C5. As a read-out for activated thymocytes IL2 production 
was measured.  
Despite expectations no IL2 was found in the supernatants (data not shown). The 
explanation for this was found after staining the cells with PI for analysis by flow 
cytometry. The thymocytes became apoptotic instead of being activated after 1C5 
treatment. 
Results, representative of two experiments, are shown in the following density 
plots showing size and granularity of the thymocytes and in the histograms 
showing the DNA content of the cells in each cell cycle. 
 
Thymocytes become apoptotic when they are held in single cell culture without 
any kind of activation (Anderson 1996). This can be seen in the histogram of the 
untreated cells. An additional so-called “pre G1-peak” appears. This pre G1-peak 
is also found in the negative controls where the thymocytes were treated with 
either rat IgG, goat anti rat alone or rat-IgG, crosslinked with goat anti rat.  
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Figure 5: 
Density plots of thymocytes, fresh, untreated and treated with control antibodies for 24h, showing 
the size (FSC) and the granularity (SSC) of the cells. The histograms show the DNA profile (FL3A) 
of these thymocytes together with the statistics for each cell cycle stage.  
File: Data.003 Sample: fresh thymocytes  
M  Low,High Events %Total  %Gated   GMean 
0    0,1023  30000 100.00  100.00   318.57
1    0, 207   1088   3.63    3.63    14.15
2  236, 353  26168  87.23   87.23   301.71
3  506, 687   1626   5.42    5.42   592.39
File: Data.004 Sample: untreated thymocytes 
M  Low,High Events %Total  %Gated   GMean 
0    0,1023  30000 100.00  100.00   243.98 
1    0, 208  11815  39.38   39.38    31.23 
2  266, 365  14280  47.60   47.60   308.38 
3  550, 682   1966   6.55    6.55   617.52 
File: Data.012 Sample: Rat-IgG-treated 
M  Low,High Events %Total  %Gated   GMean 
0    0,1023  30000 100.00  100.00   172.85 
1    0, 207  15625  52.08   52.08     6.98 
2  235, 355  12608  42.03   42.03   317.93 
3  535, 687    997   3.32    3.32   621.68 
File: Data.018 Sample: Rat-IgG+2nd ab-treat. 
M  Low,High Events %Total  %Gated   GMean 
0    0,1023  30000 100.00  100.00   167.69 
1    0, 207  15778  52.59   52.59    24.04 
2  236, 353  12423  41.41   41.41   289.16 
3  534, 686    958   3.19    3.19   583.00 
File: Data.024 Sample: only 2nd ab-treated 
M  Low,High Events %Total  %Gated   GMean 
0    0,1023  30000 100.00  100.00   204.25 
1    0, 208  12189  40.63   40.63     3.97 
2  240, 334  15213  50.71   50.71   287.28 
3  528, 619   1293   4.31    4.31   572.00 
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The treatment with PMA/ionomycin was too strong. Most of the cells were found in 
the apoptotic pre G1-peak instead of in the S-phase.  
 
 
 
 
 
 
Figure 6: 
Density plots of PMA/ionomycin treated thymocytes after 24h, showing the size (FSC) and the 
granularity (SSC) of the cells. The histogram shows the DNA profile (FL3A) of these thymocytes 
together with the statistics for each cell cycle stage.  
 
Compared to the negative controls treatment of thymocytes with the antibody 1C5 
results in a stronger pre G1-peak. Crosslinking 1C5 with a secondary antibody, 
goat anti rat, increases this shift into apoptosis.  
 
 
 
 
 
 
 
 
 
 
Figure 7: 
Density plots, histograms and statistics of thymocytes treated with 1C5 or crosslinked 1C5. 
 
These experiments gave a first hint, that the unknown protein on thymocytes might 
play a role in apoptotic events which are the central processes during thymocyte 
development. 
To prove these data 1C5-negative cells e.g. the later found “subpopulation” of 
1C5-negative CD4 SP thymocytes should be tested in the same way.  
 
File: Data.008 Sample: PMA/Iono.-treated 
M  Low,High Events %Total  %Gated   GMean 
0    0,1023  30000 100.00  100.00   130.02  
1    0, 208  23328  77.76   77.76    43.91 
2  272, 368   3911  13.04   13.04   322.34 
3  560, 720    661   2.20    2.20   638.47 
File: Data.013 Sample: 1C5-treated 
M  Low,High Events %Total  %Gated   GMean 
0    0,1023  30000 100.00  100.00    40.77 
1    0, 208  26693  88.98   88.98     6.31 
2  236, 355   3073  10.24   10.24   302.35 
3  535, 687    132   0.44    0.44   593.85
File: Data.020 Sample: 1C5+2nd ab-treated  
M  Low,High Events %Total  %Gated   GMean 
0    0,1023  30000 100.00  100.00    26.67 
1    0, 208  27976  93.25   93.25     6.41 
2  236, 350   1884   6.28    6.28   291.64 
3  535, 686     55   0.18    0.18   585.82 
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5.2. Exclusion of members of the TNFR superfamily     
Since the members of the TNFR superfamily share a high homology in their ECDs, 
it was probable that one of the members would cross-react with the antibody 1C5. 
The easiest way to check this was to investigate thymocytes of mice deficient in 
certain members of the TNFR superfamily by flow cytometry.  
Both TNFRs, TNFRI (p55) and TNFRII (p75), share very high homologies with the 
mLTβR (Force 1995). Therefore they were the first receptors to be checked to 
determine whether they were the unknown protein. 
 
 p55 TNFR-/-     p75 TNFR-/- 
 
 
 
 
 
 
 
 
 
 C57BL/6     L929 
 
 
 
 
 
 
 
 
 
 
Figure 8: 
Histograms of thymocytes from wt C57BL/6 mice and from mice deficient in p55 TNFR or p75 
TNFR after staining with rat-IgG2a for the isotype control, 5G11b as a mLTβR-specific antibody and 
1C5 for the unknown protein. Interestingly and in contrast to the literature a very small amount of 
mLTβR was detected on the thymocytes whereas a significant shift with 1C5 appeared. L929 cells, 
naturally expressing mLTβR on their surface, served as a positive control for both antibodies. 
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As shown in figure 8 thymocytes from mice deficient in p55 TNFR or p75 TNFR 
also reacted with the antibody 1C5, excluding these two TNFRs as the unknown 
protein.  
HVEM and DcR3 share not only a sequence homology but also their common 
ligand LIGHT with the LTβR which raised the question as to whether one of these 
two receptors could be the unknown protein. Earlier flow cytometric analysis with 
1C5 on thymocytes of HVEM-/- mice showed positive staining (personal 
communication Dr. P. Mueller) removing HVEM from the list of probable 
candidates. DcR3 did not need to be checked because it is a soluble receptor 
which is not detectable on the surface of cells.  
 
According to Force, 1995, CD40 is very homologous to the membrane proximal 
part of the mLTβR-ECD. As CD40 is known to be not expressed on T cells it can 
be excluded as the unknown protein without any experiment. 
 
As the biological function of the unknown protein was determined to be a role in 
apoptosis, members of the TNFR superfamily with a so-called “death domain”, DD, 
which is responsible for the apoptotic process in the receptor bearing cell, were 
the next candidates to be investigated. Therefore similar analyses on thymocytes 
of mice deficient in TRAMP/DR3, TRAIL-R and of MRL lpr/lpr mice, which natively 
carry a mutated Fas gene, were performed. These thymocytes also showed 
positive staining, excluding TRAMP/DR3, TRAIL-R and Fas as the unknown 
protein. The studies on MRL lpr/lpr mice and TRAILR-/- mice were performed in the 
lab of Dr. H. Walczak at the German Cancer Research Center in Heidelberg, 
shown in figure 10. Dr. E. Wang at the University of Cardiff communicated 
personally that he determined the positivity of thymocytes of TRAMP/DR3-/- mice 
for 1C5. 
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TRAILR-/-     MRL lpr/lpr 
 
 
 
 
 
 
 
 
 
Figure 10: 
Histograms of thymocytes from mice deficient in TRAIL-R or mutated in the Fas gene after staining 
with rat-IgG2a for the isotype control and 1C5 for the unknown protein. Again 1C5 showed a shift on 
thymocytes of both mice. On MRL lpr/lpr anti-CD95 was stained to prove the mutation in the fas 
gene. 
 
Finally OPG, another death receptor (DR) of the TNFR superfamily, can be 
excluded as the unknown protein because it is a soluble receptor like DcR3. 
 
Taken together the following TNFR superfamily members can be excluded as the 
unknown protein: p55 TNFRI, p75 TNFRII, HVEM, TRAIL-R, FAS, TRAMP, CD40 
OPG and DcR3. 
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5.3. Epitope mapping 
One possibility to more closely define an unknown protein for which an antibody 
exists is to map the epitope on the protein which was used for immunization.  
For the generation of monoclonal antibodies against mLTβR a rat was immunized 
twice with the prokaryotically expressed ECD of the mLTβR and once with the S2-
expressed ECD-hIg fusion protein. The construct for the prokaryotic expression in 
E. coli is shown in figure 11. In order to map the epitope it was necessary to 
truncate the ECD and find the smallest peptide to which the antibody 1C5 still 
binds.  
It was known that the antibody 1C5 was able to detect the prokaryotically 
expressed mLTβR-ECD on a western blot. Therefore constructs were cloned 
deleting regions from the carboxy terminus and in a second round of cloning 
deleting regions from the amino terminus for expression in E.coli and analyses by 
western blots.  
 
    1 CTCGAGAAAT CATAAAAAAT TTATTTGCTT TGTGAGCGGA TAACAATTAT 
      GAGCTCTTTA GTATTTTTTA AATAAACGAA ACACTCGCCT ATTGTTAATA 
 
                                              EcoRI 
   51 AATAGATTCA ATTGTGAGCG GATAACAATT TCACACAGAA TTCATTAAAG 
      TTATCTAAGT TAACACTCGC CTATTGTTAA AGTGTGTCTT AAGTAATTTC 
 
             BamHI/BglII 
  101 AGGAGAAATT AACTATGAGA GGATCTCACC ATCACCATCA CCATGGGATC 
      TCCTCTTTAA TTGATACTCT CCTAGAGTGG TAGTGGTAGT GGTACCCTAG 
                     M  R   G  S  H  H   H  H  H   H  G  I      
 
  151 AATTCGGCAC GAGGCGGGCT TCTGGTGGCC TCTCAGCCCC AGCTGGTGCC 
      TTAAGCCGTG CTCCGCCCGA AGACCACCGG AGAGTCGGGG TCGACCACGG 
      N  S  A  R   G  G  L   L  V  A   S  Q  P  Q   L  V  P     
         
  201 CCCTTATCGC ATAGAAAACC AGACTTGCTG GGACCAGGAC AAGGAATACT 
      GGGAATAGCG TATCTTTTGG TCTGAACGAC CCTGGTCCTG TTCCTTATGA 
       P  Y  R   I  E  N  Q   T  C  W   D  Q  D   K  E  Y  Y    
       
  251 ACGAGCCCAT GCACGACGTC TGCTGCTCCC GCTGTCCCCC AGGCGAGTTT 
      TGCTCGGGTA CGTGCTGCAG ACGACGAGGG CGACAGGGGG TCCGCTCAAA 
        E  P  M   H  D  V   C  C  S  R   C  P  P   G  E  F      
        
  301 GTCTTTGCGG TATGCAGCCG CAGCCAAGAC ACGGTTTGCA AGACTTGCCC 
      CAGAAACGCC ATACGTCGGC GTCGGTTCTG TGCCAAACGT TCTGAACGGG 
      V  F  A  V   C  S  R   S  Q  D   T  V  C  K   T  C  P     
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  351 CCATAATTCC TATAATGAAC ACTGGAACCA TCTCTCCACC TGCCAGCTGT 
      GGTATTAAGG ATATTACTTG TGACCTTGGT AGAGAGGTGG ACGGTCGACA 
       H  N  S   Y  N  E  H   W  N  H   L  S  T   C  Q  L  C   
  
  401 GCCGCCCCTG TGACATTGTG CTGGGCTTTG AGGAGGTTGC CCCTTGCACC 
      CGGCGGGGAC ACTGTAACAC GACCCGAAAC TCCTCCAACG GGGAACGTGG 
        R  P  C   D  I  V   L  G  F  E   E  V  A   P  C  T      
        
  451 AGCGATCGGA AAGCCGAGTG CCGCTGTCAG CCGGGGATGT CCTGTGTGTA 
      TCGCTAGCCT TTCGGCTCAC GGCGACAGTC GGCCCCTACA GGACACACAT 
      S  D  R  K   A  E  C   R  C  Q   P  G  M  S   C  V  Y     
         
  501 TCTGGACAAT GAGTGTGTGC ACTGTGAGGA GGAGCGGCTT GTACTCTGCC 
      AGACCTGTTA CTCACACACG TGACACTCCT CCTCGCCGAA CATGAGACGG 
       L  D  N   E  C  V  H   C  E  E   E  R  L   V  L  C  Q    
       
  551 AGCCTGGCAC AGAAGCCGAG GTCACAGATG AAATTATGGA TACTGACGTC 
      TCGGACCGTG TCTTCGGCTC CAGTGTCTAC TTTAATACCT ATGACTGCAG 
        P  G  T   E  A  E   V  T  D  E   I  M  D   T  D  V                               
                                          
  601 AACTGTGTCC CCTGTAAGCC GGGACACTTC CAGAACACTT CCTCCCCTCG 
      TTGACACAGG GGACATTCGG CCCTGTGAAG GTCTTGTGAA GGAGGGGAGC 
      N  C  V  P   C  K  P   G  H  F   Q  N  T  S   S  P  R     
 
  651 AGCCCGCTGT CAACCCCATA CCAGATGTGA GATCCAGGGC CTGGTGGAGG 
      TCGGGCGACA GTTGGGGTAT GGTCTACACT CTAGGTCCCG GACCACCTCC 
       A  R  C   Q  P  H  T   R  C  E   I  Q  G   L  V  E  A    
       
              KpnI              
  701 CAGCTCCAGG TACCCCGGGT CGACCTGCAG CCAAGCTTAA TTAGCTGAGC 
      GTCGAGGTCC ATGGGGCCCA GCTGGACGTC GGTTCGAATT AATCGACTCG 
        A  P  G   T  P  G   R  P  A  A   K  L  N   *     
 
Figure 11: 
Sequence of the ECD of mLTβR (accession number NM_010736) in the expression vector pQE32 
The translation start site (115), the stop codon (742) and the 6x His tag (127) are part of the vector. 
The insert is cloned with BamHI/BglII (146) and KpnI (709). The last 8 amino acids of the signal 
peptide and the following 12 amino acids, which are called ”spacer” in this work, start at position 
166 followed by the four cysteine rich regions starting at positions 226 (D1), 349 (D2), 475 (D3) and 
613 (D4). 
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5.3.1. Cloning of the truncated ECDs 
For the first round of cloning the following primers were designed. The 5’ primer, 
introducing a BamHI site at position +66 of the mLTβR-ECD cDNA, leaving only 
24 bp of the 90 bp for the signal peptide, was the same for all three new 
constructs. The 3’ primers, adding a KpnI-site, start at different bases in the cDNA 
so that finally products were amplified without the fourth (∆D4), the third and the 
fourth (∆D4,3), and the second, third and fourth cysteine-rich domains (CRDs) 
(∆D4,3,2). As a template for the PCRs the pcDNA3 plasmid containing the whole 
mLTβR was chosen.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 12: 
PCR for cloning the truncated proteins; round I 
The PCR products and their individual water controls (each 5µl) were checked on a 1% agarose 
gel before cloning into pCR®2.1-TOPO®. Molecular weight standard XIV: 1µg. 
 
 
For the second round of cloning the 3’ primer, using the KpnI-site 45 bp upstream 
of the carboxy terminus of the ECD, was the same for all three constructs. Coming 
from the amino terminus primers were designed in order to delete the first 20 
amino acids (-20aa), the first 39 amino acids (-42aa) or the first 61 amino acids  
(-61aa). Each primer added a BamHI-site to the 5’ of each PCR product.  
24/90 sp D4 D1 D2 D3 5’ 3’ ECD 
24/90 sp D1 5’ 3’ ∆D4,3,2
24/90 sp D1 D2 5’ 3’ ∆D4,3 
24/90 sp D1 D2 D3 5’ 3’ ∆D4 
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Figure 13: 
PCR for cloning the truncated proteins; round II 
After purifying the PCR products they were checked on a 1% agarose gel (each 2µl) before cloning 
into pCR®2.1-TOPO®. Molecular weight standard XIV: 1µg. 
 
The TOPO TA Cloning®  system was used for cloning these PCR-products before 
finally inserting them into the expression vector pQE32. As a last control, 
sequencing of all clones with the right restriction pattern was performed. Only the 
ones  in frame and without any mutation were chosen for further work. 
24/90 sp D4 D1 D2 D3 5’ 3’ ECD 
5’ -61aa 
5’ -42aa 
5’ -20aa D4 D1 D2 D3 3’ 
D4 D2 D3 3’ 
D4 
D1
D2 D3 3’ 
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Figure 14: 
1% agarose gel of all constructs cloned into pQE32 for the expression of the truncated proteins. 
Restriction digest of 2µg of each DNA was performed with BamHI/KpnI (lanes 3-9). The construct 
with the whole ECD was also cut with EcoRI/KpnI (lane 2). The size of each construct is listed. 
Molecular weight standards X and XIV: each 1µg. 
 
All clones were cut with the enzymes used for cloning, BamHI and KpnI. Each 
plasmid showed a band at 3.4 kb for the vector and an insert of the expected size. 
Only the original clone with the whole ECD could not be cut with these two 
enzymes because the BamHI-site was destroyed during BamHI/BglII-cloning. 
EcoRI/KpnI digest was used as an additional control resulting in the release  of a 
621 bp fragment. The additional bands might be due to EcoRI star activity 
because the restriction buffer was not optimal for the EcoRI- but necessary for the 
KpnI-digest.  
construct size 
ECD 563 bp 
∆D4 458 bp 
∆D4,3 320 bp 
∆D4,3,2 194 bp 
-61aa 365 bp 
-42aa 434 bp 
-20aa 491 bp 
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5.3.2. Expression of the truncated proteins 
 
  1 mrlprasspc glawgplllg lsgllvasqp  
  
 31 qlvppyrien qtcwdqdkey yepmhdvccs 
  
 61 rcppgefvfa vcsrsqdtvc ktcphnsyne  
 
 91 hwnhlstcql crpcdivlgf eevapctsdr 
 
121 kaecrcqpgm scvyldnecv hceeerlvlc  
 
151 qpgteaevtd eimdtdvncv pckpghfqnt 
 
181 ssprarcqph trceiqglve aapgtsysdt  
 
211 icknppepga mlllaillsl vlfllfttvl 
 
241 acawmrhpsl crklgtllkr hpegeesppc  
 
271 papradphfp dlaepllpms gdlspspagp 
 
301 ptapsleevv lqqqsplvqa releaepgeh  
 
331 gqvahgangi hvtggsvtvt gniyiyngpv 
 
361 lggtrgpgdp pappeppypt peegapgpse  
 
391 lstpyqedgk awhlaetetl gcqdl 
 
Figure 15: 
Protein sequence of the mLTβR 
The mLTβR consists of a signal peptide sp (aa1-30), an ECD (aa 31-223), a TMD (aa224-244) and 
an ICD (aa245-415). Its ECD is divided into four cysteine rich domains (gray shaded):  
D1 (aa42-81), D2 (aa82-124), D3 (aa125-170) and D4 (aa171-213). In the ECD there are 10 
disulfide bonds   and two glycosylation sites  (accession number  P50284). 
The arrows mark the amino terminus (aa25) and the carboxy terminus (aa205) of the protein which 
was used for immunization.  
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Figure 16: 
Schematic view of the truncated proteins, expressed in E. coli 
 
All clones were expressed in M15 E. coli and enriched with Ni-NTA technology.   
Figure 17 shows all expressed truncated proteins on a 17% silver stained SDS-
PAA gel. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 17: 
17% silver stained SDS-PAA gel showing all truncated ECDs (*) and the whole ECD (*) after 
enrichment with Ni-NTA technology; 100µl of each eluted protein and 20µl of the broad range 
molecular weight standard were subjected to the gel.  
 
Length 
[aa] 
Calcul. 
MW 
[kD] 
Position  
SDS-
PAA gel 
ECD 209 23.4 24-30
∆D4 174 19.6 24
∆D4,3 128 14.5 16
∆D4,3,2 86 9.7 9
-61aa 143 16.0 21
-42aa 166 18.4 24
-20aa 185 20.8 27
D1 
D1 D4D3D28/30sp N’ C’ 
D4D3D2N’ C’ 
D4D3D2N’ C’ 
D1 D4D3D2N’ C’ 
ECD 
-61aa 
-42aa 
-20aa 
D1 D3D28/30sp N’ C’ ∆D4 
D1 D28/30sp N’ C’ ∆D4,3 
D1 8/30sp N’ C’ ∆D4,3,2 
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5.3.3. Western blots and immunodetection of the truncated proteins 
The experiments to check whether all proteins could be blotted and detected on 
the membrane were performed with an anti-RGS-His4 or with a polyclonal anti 
mLTβR serum.  As shown in figure 18 all proteins were detectable in this way. 
 
polyclonal rabbit anti mLTβR serum  mouse anti RGS-His4 
 
 
 
 
 
 
 
 
 
Figure 18: 
Western blots of all truncated ECDs of mLTβR, detected with polyclonal rabbit anti mLTβR serum 
(left) and mouse anti RGS-His4 (right). The same amounts of proteins were loaded like on the silver 
stained gel. 
 
Since four different monoclonal rat anti mLTβR antibodies had been generated, it 
was interesting to map the epitopes of all of them.  
From earlier competition assays (Muller, 2001) three different epitopes were 
expected for the four monoclonal antibodies. This was supported by the epitope 
mapping.  
                                                                                                                       Results 
73 
5D12a2     5G11b 
 
 
 
 
 
 
 
 
 
Figure 19: 
Western blots of all truncated ECDs of mLTβR, detected with the mLTβR specific rat monoclonal 
antibodies 5D12a2 (left) and 5G11b (right). The same amounts of proteins were loaded like on the 
silver stained gel. 
 
5D12a2 does not bind the ECD of mLTβR anymore if the second domain is deleted 
indicating that the epitope of 5D12a2 is located in the second domain which is part 
of the ligand binding domain (Force et al., 1995).  
As 5G11b cannot detect the protein if the first 39 amino acids are missing  
(“-42aa”) but still binds if the first 20 amino acids are deleted, it is clear that the 
antibody binds the first 19 amino acids of the first cysteine rich region.  
 
12H11      1C5 
 
 
 
 
 
 
 
 
 
Figure 20: 
Western blots of all truncated ECDs of mLTβR, detected with the monoclonal rat antibody 12H11 
(left) and the cross-reacting monoclonal rat antibody 1C5 (right). The same amounts of proteins 
were loaded like on the silver stained gel. 
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The antibodies 12H11 and 1C5 had competed with each other and showed 
binding to the same epitope on the membrane. Both bind the first 20 amino acids 
of the ECD of mLTβR. They bind every construct which is deleted from the 
carboxy terminus down to the smallest one which represents only a part of the 
signal peptide (8aa), the “spacer” of 12 amino acids between the signal peptide 
and the cysteine rich regions and the first cysteine rich domain. Binding was lost 
when the first 20 amino acids from the amino terminus were deleted. This 
indicates that the epitope of 12H11 and 1C5 is localized upstream of the 
conserved cysteine rich regions. Therefore the possibility exists that the unknown 
protein might not be a member of the TNFR superfamily. 
Eight amino acids of the smallest construct to which 1C5 binds, ∆D4,3,2, belong to 
the signal peptide of the mLTβR. The mature mLTβR no longer has the signal 
peptide but can be detected with 1C5 in flow cytometric analysis. Thus the 
antibody 1C5 must bind to the “spacer” of 12 amino acids.  
In addition 12H11 and 1C5 bind the same epitope of the mLTβR whereas only 
1C5 cross-reacts with an antigen on the surface of thymocytes; 12H11 has lost its 
cross-reactivity with the unknown protein on thymocytes. This might be due to an 
initially lower affinity of 12H11 which decreased further down with the storage of 
the antibody. Testing the affinity of both antibodies with titration curves will help to 
find an explanation for this phenomenon.  
Taken together the epitope mapping supported the findings of the competition 
assays. There are three different epitopes recognized by the four monoclonal 
antibodies and only 12H11 and 1C5 detect the same epitope of the mLTβR and 
compete with each other.  
 
In order to further narrow down the epitope its 12 amino acids were compared to 
the human LTβR. There is a homology of 60% between human and mouse LTβR 
for the whole protein and of 75% regarding these 12 amino acids. 
 
Q L VPPY  RI  ENQT       mLTβR 
Q A VPPY AS ENQT        hLTβR 
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To check whether 1C5 also binds the hLTβR a western blot with the S2 expressed 
hLTβR-Ig fusion protein was performed.  
 
 
 
 
 
 
 
 
Figure 21: 
Western blot of mouse and human LTβR-Ig fusion protein and mLTβR, prepared from L929 cells, 
detected with the antibody 1C5.  
(The “band” in the lane with the standard is not a protein band but a scratch on the membrane).  
 
Figure 21 shows that 1C5 can bind the hLTβR-hIg fusion protein as well as the 
mLTβR. The mLTβR was expressed in S2 cells as a hIg fusion protein or prepared 
from the membrane fraction of L929 cells, a mouse fibroblast cell line. Ware 
(1995) observed a mass of 61kd for the human LTβR. The mature human LTβR 
protein has a calculated mass of 44kD for its 405aa. The difference between the 
calculated and the observed molecular weight (MW) of the human LTβR might be 
due to glycosylation at the two N-glycosylation sites in the ECD. The calculated 
mass of the mature mouse LTβR protein is 42kD for its 385aa. As the mouse 
LTβR also has two N-glycosylation sites its true MW is ~ 60kD like it was seen in 
the western blot.  
It needs to be mentioned here that residues of proteinG were found in the 
proteinG-purified antibody 1C5. Binding of proteinG to the Ig-tail of the fusion 
proteins of mLTβR and hLTβR needs to be excluded. Therefore tests with the 
untagged ECD of the hLTβR need to be performed in order to prove the binding of 
1C5 to the hLTβR. 
 
With this epitope homology searches with the NCBI protein BLAST 
(http:/www.ncbi.nih.gov/BLAST/)(blastp for short, nearly exact matches) were 
carried out. Nearly 70 proteins (50% are unnamed, RIKEN or EST products) 
matched over a minimum of four amino acids. None of the known proteins was a 
member of the TNFR superfamily again pointing to a protein which does not 
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belong to this group of receptors. With rpsblast no conserved domain was 
detectable for these 12 amino acids although they are shared by so many different 
proteins. The next step will be to find out which of the matching proteins is 
expressed on the surface of thymocytes. 
Alignments with swissprotplus on Bioccellerator applying Smith-Waterman 
algorithm (performed by Dr. A. Hotz-Wagenblatt, HUSAR Bioinformatics Lab, 
German Cancer Research Center) revealed numerous prokaryotic proteins, 
human and mouse LTβR and chicken TGFβ3 to be homologous to the found 1C5-
epitope. Chicken and mouse TGFβ3 have a 84% identity. Therefore the epitope 
was compared to mTGFβ3 and showed a 88% similarity and a 33% identity. 
Beside the other 70 matching proteins now TGFβ3 is the main candidate to be the 
protein with which 1C5 cross-reacts. 
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5.4. Differentiation of thymocytes and splenocytes expressing the   
unknown protein 
5.4.1. Thymocytes 
Four colour flow cytometric analysis was performed in order to find out if the 
unknown protein with which the antibody 1C5 cross-reacts is expressed on all 
thymocytes or only on a certain subpopulation depending on the stage of 
maturation/development. Defining a maturation-dependent expression would make 
this unknown protein again very interesting and could involve its biological 
function, such as a role in apoptosis, in the thymocyte development where 
apoptosis is a major event.  
The data are representative of four different experiments. 
Thymocytes from C57BL/6 mice and from mice deficient in the LTβR, excluding all 
possible binding of 1C5 to the LTβR on thymic stromal cells, were stained with 
1C5, CD4 and CD8a for a first survey. Thymocytes of LTβR-/- mice exhibited a 
small difference in their distribution of CD4 SP and CD8 SP cells compared to wt 
mice. Recent thymic emigrants (RTE), the most mature single-positive thymocytes 
(SP), accumulate in the thymi of LTβR-/- mice and their numbers double (Boehm et 
al. 2003).  
 
For flow cytometric analysis the thymocyte population was determined in region 1 
(R1) according to the size (FSC) and the granularity (SSC) of  the thymocytes. 
That way 77% of all cells in the wt thymus and 79.5% of all cells in the LTβR-/- 
thymus were chosen.  
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 C57BL/6               LTβR-/- 
 
 
 
 
 
 
 
 
Figure 22: 
Density plots of isolated thymocytes from wt and LTβR-/-  mice for the determination of region 1 
(R1) , including all single thymocytes, excluding all other cell types and doublettes. 
 
The antibody 1C5 bound to 85% of thymocytes of LTβR-deficient mice and 90% of 
thymocytes from wt mice. 
 
 C57BL/ 6                 LTβR-/- 
 
 
 
 
 
 
 
 
 
       
 
 
 
 
 
 
 
 
Figure 23: 
Density plots and dot plots of thymocytes from wt and LTβR-/- mice, gated for region 1 (R1), 
showing the staining with the antibody 1C5 and the determination of the 1C5-positive (R9) and 
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1C5-negative (R10) populations. 1C5-positivity was determined with regard to the single staining 
pattern, the autofluorescence and the isotype controls. Dot plots were chosen for the following 
figures because they show every single event which is necessary for some very small 
subpopulations of the thymocytes. 
 
To obtain the first overview regions were set for 1C5-positive and 1C5-negative 
thymocytes looking for their expression of CD4 and CD8a. Figure 24 shows that 
there might be a difference in the maturation of CD4 single-positive and CD8 
single-positive thymocytes in regard to their expression of the unknown protein. 
There were nearly no CD8 single-positive thymocytes which did not express the 
unknown protein whereas the amount of 1C5-positive and 1C5-negative CD4 
single-positive thymocytes seemed to be same. 
 
C57BL/ 6 
          R1: all thymocytes          R1+R9:1C5-positive          R1+R10: 1C5-negative 
 
 
 
 
 
 
 
LTβR-/- 
          R1: all thymocytes         R1+R9:1C5-positive          R1+R10: 1C5-negative 
 
 
 
 
 
 
 
Figure 24: 
Dot plots of  thymocytes from wt and LTβR-/- mice, gated for region 1 (R1),  showing the CD4/CD8 
expression determining the different thymocyte subpopulations (R2-R8). Application of region 9 
(R9), representing the 1C5-positive cells, and region 10 (R10), representing the 1C5-negative cells 
shows a difference in the CD4/CD8 expression between 1C5-positive and 1C5-negative 
thymocytes for both mouse strains. 
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The maturation of thymocytes can be followed by the observation of the 
expression of CD4 and CD8. Sant’Angelo et al (1998) suggested a model to better 
understand the thymocyte maturation. According to this model regions were 
chosen to further investigate the expression of the unknown protein during the 
thymocyte maturation. 
 
 
Figure 25: 
Model of thymocyte maturation according to Sant’Angelo et al, 1998.  
Regions R3-R8 were set in figure 24 for further analysis. 
 
During thymocyte maturation CD69, activation inducer molecule (AIM), a C-type 
lectin, is upregulated after positive selection in the double-positive stage (DP) and 
downregulated right before the single-positive cells leave the thymus as RTE. 
Therefore CD69/AIM was used as an additional differentiation marker for  
thymocyte maturation. The expression of the unknown protein was compared with 
this marker to investigate whether the unknown protein might be regulated during  
thymocyte maturation. 
 
 
Figure 26: (next two pages)  
Expression of the unknown protein, stained with 1C5 (x-axis) in comparison to CD69 (y-axis) in the 
different stages (R2-R8) of thymocyte maturation of wt and LTβR-/- mice. 
The regions were set in figures 22 and 24 .   
  CD4+CD8+CD69-TCRlo„small“
  CD4+CD8+CD69-TCRlo„large“ 
CD4loCD8lo/+CD69+TCRint
CD4+CD8loCD69+TCRint/hi
       CD4loCD8lo/+CD69+TCRhi
       CD4loCD8+CD69+TCRint/hi
         CD4-CD8+CD69-TCRhi
CD4+CD8-CD69-TCRhi 
Positive Selection 
R3 
R7 
R4 
R3 
R5 
R4 R8 
R6 
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  C57BL/6        LTβR-/- 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
R1 
R1+R2 
R1+R3 
R1+R4 
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   C57BL/ 6         LTβR-/- 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
R1+R5 
R1+R6 
R1+R7 
R1+R8 
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For a better understanding all the information of the flow cytometric analyses 
above are delineated in the following two diagrams. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 27: 
Summary of  the analyses shown in figure 26 with the use of Sant’Angelo’s model. 
 
 
In accordance with Sant’Angelo’s model CD69 was upregulated in wt mice after 
the double-positive stage (from 8% to 78%) and downregulated in the most mature 
single-positive thymocytes (63% for CD4 and 46% for CD8). In LTβR-/- mice a 
lower percentage of CD69-positive cells was found in the single-positive stage 
(30% for CD4 and 17% for CD8). This might be explained by the accumulation of 
CD69-negative RTEs in the LTβR-/-  mice. 
  
Compared to the CD69 expression, the expression of the unknown protein also 
seemed to be regulated, but in a different way. The expression is independent of 
0.9% of all thymocytes 
77.5% 1C5+ 
18.1% CD69+ 
1.2% of all thymocytes 
46.4% 1C5+ 
80.9% CD69+ 
86.6% of all thymocytes 
94.1% 1C5+ 
  8.2% CD69+ 
0.8% of all thymocytes 
93.8% 1C5+ 
64.3% CD69+ 
1.2% of all thymocytes 
97.8% 1C5+ 
45.6% CD69+ 
1.6% of all thymocytes 
76.1% 1C5+ 
78.3% CD69+ 
6.6% of all thymocytes 
46.6% 1C5+ 
62.5% CD69+ 
DP 
CD8 SP 
CD4 SP 
LTβR-/- 
0.8% of all thymocytes 
77.2% 1C5+ 
21.4% CD69+ 
1.3% of all thymocytes 
55.0% 1C5+ 
61.1% CD69+ 
80% of all thymocytes 
92.5% 1C5+ 
  7.3% CD69+ 
0.7% of all thymocytes 
94.7% 1C5+ 
58.9% CD69+ 
2.3% of all thymocytes 
98.3% 1C5+ 
17.4% CD69+ 
1.9% of all thymocytes 
76.6% 1C5+ 
70.3% CD69+ 
12.7% of all thymocytes 
47.1% 1C5+ 
30.1% CD69+ 
DP 
CD4 SP 
CD8 SP 
C57BL/6 
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the LTβR since the percentage of 1C5-positive cells in the different thymocyte 
subpopulations did not differ between wt and LTβR-/- mice.  
During the double-positive stage (R3) nearly all thymocytes (94%) were 1C5-
positive. With the next step, where cells become “double dull” (CD4loCD8lo) (R4), 
the unknown protein was downregulated to 76% while the expression of CD69 
increased. In the following CD4hiCD8lo stage (R7) the percentage of 1C5-positive 
cells dropped and the number of CD69-positive cells remained nearly stable. Cells 
becoming mature CD4 single-positive thymocytes (R8) decreased their CD69 
expression and 47% of them maintained the expression of the unknown protein.  
The pathways to develop into either CD4 single-positive or CD8 single-positive 
thymocytes bifurcate in the CD4hiCD8lo stage (R7). The CD4 single-positive 
thymocytes need only one last step before leaving the thymus whereas the CD8 
single-positive thymocytes have to become “double dull” (R4) again before finally 
abrogating their CD4 expression. From “double dull” to CD4loCD8hi (R5) the 
thymocytes decreased their CD69 expression and strongly increased the 
expression of the unknown protein up to 94%. Before leaving the thymus as CD8 
single-positive T cells (R6) the expression of the unknown protein was further 
increased to 98% while CD69 expression was further lowered.  
Additional analysis with 1C5, CD3, and CD69 supported these findings. Only 10% 
of the wt thymocytes and 14% of the LTβR-/- thymocytes were 1C5-negative. 
Approximately 80% of these cells are CD3hiCD69+/- defining these cells as the 
most mature thymocytes. These mature thymocytes probably constitute the CD4 
single-positive population because 53% of CD4 single-positive thymocytes were 
1C5-negative whereas only 2% of the CD8 single-positive thymocytes were 1C5-
negative.  
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C57BL/ 6  
       R1: all thymocytes          R1+R9:1C5-positive         R1+R10: 1C5-negative 
 
 
 
 
 
 
 
 
LTβR-/- 
       R1: all thymocytes          R1+R9:1C5-positive          R1+R10: 1C5-negative 
 
 
 
 
 
 
 
Figure 28: 
Dot plots of  thymocytes from wt and LTβR-/- mice, gated for region 1 (R1),  showing the CD3/CD69 
expression of all thymocytes.  Application of region 9 (R9), representing the 1C5-positive cells, and 
region 10 (R10), representing the 1C5-negative cells, shows a difference in the CD3/CD69 
expression between 1C5-positive and 1C5-negative thymocytes for both mouse strains.  
 
In order to detect the very early thymocytes, the CD4-CD8- double-negative cells 
(DN) which are part of region 2 (R2), staining of the thymocytes with anti-CD117 
was performed. Less than 0.2 % of all thymocytes were CD117-positive cells. With 
these few cells no clear result could be obtained concerning the expression of the 
unknown protein in the very early thymocyte population. 
The results of the flow cytometric analyses with 1C5, CD3, CD4, CD8a, and CD69 
hinted at an association of the unknown protein to the T cell development and  
maybe also to the CD4/CD8 lineage commitment.  
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5.4.2. Splenocytes 
As there was a difference observed between the percentage of 1C5-positive cells 
in the CD4 single-positive and the CD8 single-positive thymocytes it became 
important to know not only whether mature peripheral lymphocytes express the 
unknown protein but also whether there is a difference between CD4-positive and 
CD8-positive T cells. Therefore similar analyses were again performed with anti-
CD3, anti-CD4, anti-CD8a, anti-CD45R/B220, anti-CD69, and 1C5, this time on 
splenocytes of C57BL/6 mice and of LTβR-/- mice. The following data represent the 
results of four different experiments.  
 
         C57BL/6         LTβR-/-   
 
           
 
 
 
 
 
 
Figure 29: 
Density plots of isolated splenocytes  from wt and LTβR-/- mice for the determination of region 1 
(R1), including all lymphocytes. 
 
Region 1 (R1) was chosen to represent all lymphocytes. 63% and 68% of all cells 
were lymphocytes in wt and in LTβR-/- mice respectively. 
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The percentage of 1C5-positive cells in the spleen was much lower than in the 
thymus and nearly the same for LTβR-/- mice and wt mice with 5.3% and 4.7% 
respectively, shown in figure 30. 
 
         C57BL/ 6                  LTβR-/- 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 30: 
Density plots and dot plots of isolated splenocytes  from wt and LTβR-/- mice for the determination 
of region 2 (R2) representing 1C5-positive cells. 
 
In the T cell population the percentage of 1C5-positive cells was nearly the same 
in wt and LTβR-/- mice with 1.4% 1C5+ T cells in wt and 1.3% 1C5+ T cells in the 
LTβR-/- mice. Regarding the CD4+ and the CD8+ subpopulations again no 
difference was found between both mouse strains and, in contrast to the thymus, 
between the subpopulations themselves either.  
These results are plotted in figure 31 for the LTβR-/- mice and summarized in table 
1. Only the plots of the LTβR-/- splenocytes are shown as an example because of 
the similar results of the wt mice. 
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A1)       A2) 
 
 
 
 
 
 
 
B1)       B2)    
 
 
 
 
 
 
 
 
C1)       C2) 
 
 
 
 
 
 
 
 
 
Figure 31: 
Dot plots of isolated splenocytes from LTβR-/- mice , gated for region 1 (R1), stained with anti-CD3 
(A1), anti-CD4 (B1) or anti-CD8a (C1). Region 2 (R2) was set for the positive cells of each staining 
which were further analysed for their expression of the unknown protein (A2, B2, C2). 
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In the thymus less than 0.2% of all lymphocytes were CD45R/B220-positive B-
cells. It was impossible to determine the expression of the unknown protein in 
these few thymic B cells. However there was a clear subpopulation of B cells in 
the spleen also expressing the unknown protein (6.4% in wt, 5.7% in LTβR-/- mice). 
  
D1)       D2) 
 
 
 
 
 
 
 
Figure 32: 
Dot plots of isolated splenocytes from LTβR-/- mice, gated for region 1 (R1), stained with anti-
CD45R/B220 (D1). Region 2 (R2) was set for the CD45R/B220-positive B cells,  which were further 
analysed for their expression of the unknown protein (D2). 
 
 
 
 
 
 
 
 
 
 
Table 1: 
Percentage of 1C5-positive cells in the different subpopulations of mature T and B cells of both 
mouse strains. 
 
These results identified B cells as the major mature lymphocytes bearing the 
unknown protein in the spleen. The difference between CD4 SP and CD8 SP 
thymocytes did not continue in the mature T cells.  
 
 
Wt 
 % of 1C5+ cells
LTβR-/- 
% of 1C5+ cells
CD4 0.81 1.0 
CD8 1.43 1.4 
CD3 1.43 1.26 
CD45R/B220 6.37 5.72 
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CD69 is a marker not only for developing thymocytes but also for activated 
peripheral leukocytes. For example, the CD69 expression on T cells increases 
immediately after PMA treatment reaching a maximum level after 12 hours. After 
24 hours the expression has declined partially and persists for at least 48 hours. 
CD69-mRNA becomes detectable after 30-60 minutes, reaches its maximum level 
by 6 hours, and then vanishes (López-Cabrera et al.,1993). 
Nearly 7% of all wt lymphocytes and 8% of all LTβR-/- lymphocytes were CD69-
positive. In wt mice 32% of all CD69-positive cells were 1C5-positive whereas in 
LTβR-/- mice 25% of the activated lymphocytes expressed the unknown protein.  
 
E1)       E2) 
 
 
 
 
 
 
 
Figure 33: 
Dot plots of isolated splenocytes from LTβR-/- mice, gated for region 1 (R1), stained with anti-CD69 
(E1). Region 2 (R2) was set for the CD69-positive lymphocytes  which were further analysed for 
their expression of the unknown protein (E2). 
 
These results indicated a possible role for the unknown protein in the activation of 
lymphocytes. Therefore the composition of the activated lymphocytes was further 
investigated. 
                                                                                                                       Results 
91 
In wt mice 44% of the activated cells were T cells and 45% were B cells. LTβR-/- 
mice showed a different distribution with 36% T cells and 49% B cells (figures 34 
and 38).  
Activated T cells were further analysed with the cross-reacting antibody 1C5. The 
percentage of 1C5-positive cells in this subpopulation of T cells (7.7% and 5.6% in 
wt and LTβR-/- mice respectively) is much higher than the overall percentage of 
1C5-positive cells in the whole T cell population (1.4%, 1.3%).  
 
         C57BL/6         LTβR-/- 
 
 
 
 
 
 
 
  
Figure 34: 
Splenocytes of wt and LTβR-/- mice, gated for R1 (figure 30) representing all lymphocytes, and 
gated for R2 (figure 33), representing all activated CD69+ lymphocytes, showing the percentage of 
CD3+ T cells on CD69+ lymphocytes. Region 3 (R3) represents all activated T cells which were 
further analysed for their expression of the unknown protein, shown in figure 35:  
 
         C57BL/6          LTβR-/-  
 
 
 
 
 
 
 
 
 
Figure 35: 
Splenocytes of wt and LTβR-/- mice, gated for R1, R2 and R3 representing all CD69+ CD3+ T cells 
showing the percentage of 1C5+ cells in the activated T cell population. 
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Therefore it was interesting to see whether there was a difference between 
activated CD4 T cells and CD8 T cells. In wt mice 34.5% of all activated 
lymphocytes were CD4 T cells and 6.7% were CD8 T cells. Again the composition 
was different in LTβR-/- mice with 26% CD4 and 4.8% CD8 T cells. The percentage 
of 1C5 positive activated CD4 T cells was nearly the same in wt and LTβR-/- mice 
with 3.1% and 3.8% respectively. Interestingly the percentage of 1C5 positive CD8 
T cells was much higher with 8.6% and 11.2%, also showing a difference between 
wt and LTβR-/- mice (summarized in table 2).  
 
          C57BL/6          LTβR-/- 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 36: 
Dot plots of activated lymphocytes, gated for R1 and R2, representing all CD69+ lymphocytes in the 
spleen of wt and LTβR-/- mice. R3 represents all activated CD4 T cells (upper panel) which were 
further analysed for their expression of the unknown protein (lower panel) 
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          C57BL/6          LTβR-/- 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 37: 
Dot plots of activated lymphocytes, gated for R1 and R2, representing all CD69+ lymphocytes in the 
spleen of wt and LTβR-/- mice. R4 represents all activated CD8 T cells (upper panel) which were 
further analysed for their expression of the unknown protein (lower panel) 
 
 
 
 
 
 
 
 
 
 
 
Table 2: 
Summary of 1C5-positivity on activated T cells and its subpopulations. 
 
In the thymus a difference was determined between CD4 SP and CD8 SP 
concerning the percentage of 1C5 positive cells. This difference was not found on 
mature T cells but appears again on activated T cells.
 wt LTβR-/- 
CD69+ 7% 8%
%1C5+/CD69+ 32% 25%
%CD3+/CD69+ 44% 36%
%1C5+/CD3+CD69+ 7.7% 5.6%
%CD4+/CD69+ 34.5% 26.2%
%1C5+/CD4+CD69+ 3.1% 3.8%
%CD8+/CD69+ 6.7% 4.8%
%1C5+/CD8+CD69+ 8.6% 11.2%
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The CD45R/B220+ B cells portion of the CD69+ cells was also analysed for its 1C5 
positivity. 
 
          C57BL/6          LTβR-/- 
 
 
 
 
 
 
 
 
 
Figure 38: 
Splenocytes of wt and LTβR-/- mice, gated for R1 representing all lymphocytes, and gated for R2, 
representing all activated CD69+ lymphocytes, showing the percentage of CD45R/B220+ B cells on 
CD69+ lymphocytes. Region 3 (R3) represents all activated B cells which will be further analysed 
for their expression of the unknown protein, shown in figure 39:  
 
Nearly 35% of all activated CD69+CD45R/B220+ cells in the wt mice and 23% in 
the LTβR-/- mice demonstrated the expression of the unknown protein. 
 
          C57BL/6           LTβR-/-  
 
 
 
 
 
 
 
 
 
Figure 39: 
Splenocytes of wt and LTβR-/- mice, gated for R1, R2 and R3 reprenting all CD69+ CD45R/B220+ B 
cells showing the percentage of 1C5+ cells in this population of activated B cells. 
 
With these analyses it was clarified that the unknown protein is expressed on 35% 
of activated B cells in the spleen of wt mice and 23% in the spleen of LTβR-/- mice. 
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6. Discussion  
The monoclonal rat anti mouse LTβR antibody 1C5 detects the mLTβR under 
native (flow cytometric analyses) and under denaturing conditions (western-blot). 
Binding to the unknown protein has only been shown for the native protein on 
thymocytes and activated mature B and T cells yet. It is not known whether 1C5 
also detects the unknown protein in its denatured form. First attempts to isolate 
and blot the unknown protein from thymocytes failed due to technical problems. 
The epitope of the monoclonal rat anti mouse LTβR antibody 1C5 was narrowed 
down to the first 12 aa of the mature protein under denaturing conditions.  
Binding to the human LTβR which has a 75% homology to the mouse receptor in 
these 12 aa was found by western blot. Interestingly testing 1C5 on A375, a 
human melanoma cell line, by flow cytometric analysis under native conditions 
showed no binding (data not shown).  
From these data it can be concluded that the epitope is necessary for binding but 
may not be sufficient for binding.  
The secondary structure of the LTβR and / or the unknown protein might influence 
the binding of 1C5. 
There is a slight possibility that the prokaryotically expressed proteins were not 
fully denatured in SDS-gels and western-blots. Binding of 1C5 to these blotted 
proteins might not only be due to the epitope but also to remaining secondary 
structures. To solve this problem binding of 1C5 to a synthetic peptide of these 12 
aa should be investigated under denaturing conditions, i.e. western-blot, and 
under native conditions, i.e. immobilized to an ELISA-plate.  
If 1C5 binds the synthetic peptide it will be clear that the epitope is sufficient for 
binding and homology searches may help to define the unknown protein.  
Finding a conformation-dependent binding would lead to the necessity to do any 
experiment under native conditions. Homology searches would not lead any 
further.  
There is a small possibility that the antigen to which 1C5 binds is not a protein at 
all. Observations were made of peptide-specific antibodies also cross-reacting with 
other structures like glycosylated proteins, DNA, or lipids. If this were the case for 
1C5 it would decrease the chance to find the unknown protein dramatically.  
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Independent from these speculations homology searches applying NCBI protein 
BLAST were performed and revealed ~70 proteins which match the epitope with 
four or more amino acids. None of the members of the TNFR superfamily was 
found in this list of homologous proteins, which supports the finding that the 
epitope is located upstream of the conserved CRDs.  
It is interesting that an antibody which binds to such a common epitope exhibits 
distinct staining patterns on subsets of thymocytes and splenocytes.  
In order to come closer to the unknown protein the homologous proteins will be 
checked to determine whether they are expressed on the surface of thymocytes 
and activated CD8 T cells and B cells.  
 
In 2003 Schmitz et al. performed gene expression analysis of thymocytes and 
found 244 differentially expressed DP thymocyte genes induced or repressed by 
TCR triggering in vivo. Checking whether one of these 244 proteins consists of the 
epitope might lead to the elucidation of the unknown protein which was found to be 
upregulated in the DP stage of thymocyte development.  
 
With regard to the Smith-Waterman algorithm, TGFβ3 now seems to be the main 
candidate for the unknown protein. If TGFβ3 is a plausible candidate the easiest 
way to check this assumption will be to perform flow cytometric analysis of 
thymocytes of TGFβ3-/- mice like it was performed for the earlier excluded TNFR 
superfamily members. Since these mice were not available RT-PCRs were 
performed on thymocytes and on sorted 1C5+ and 1C5- thymocytes to check  first 
whether these cells express TGFβ3. Semiquantitative comparison to the 
expression of β-actin showed no significant difference between 1C5+ and 1C5- 
thymocytes (data not shown). These analyses do not exclude TGFβ3 from the list 
of probable candidates although there was no difference between 1C5+ and 1C5- 
thymocytes. There might be a slight difference on mRNA level which is only 
detectable in quantitative real-time PCR but which might lead to a very low 
expression on 1C5- thymocytes which is under the detection level of flow 
cytometric analysis.  
To elucidate this hypothesis quantitative real-time PCR on sorted thymocytes need 
to be performed. 
In parallel it would be useful to transfect 1C5- cells with a TGFβ3-expressing 
vector and look for 1C5-binding by flow cytometry.  
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Four colour flow cytometric analyses on thymocytes of wt and LTβR-/- mice led to 
two conclusions. First, the unknown protein is regulated during thymocyte 
development and second, this regulation is independent of the LTβR.  
This independence was demonstrated since there was no difference in the 
expression of the unknown protein in the different thymocyte subpopulations 
between wt and LTβR-/- mice.  
 
A difference was found between the development of CD4 SP and CD8 SP 
thymocytes. Whereas future CD4 SP thymocytes downregulate the unknown 
protein to 47% after positive selection, future CD8 SP cells upregulate it to 98% 
after leaving the shared pathway at the CD4hiCD8lo step. Up to now it is not clear 
which parameter determines the commitment and differentiation to CD4 SP or 
CD8 SP thymocytes. Signal strength or signal duration of the TCR-peptide-MHC 
complex, transcription factors, transcription repressors and members of the 
NOTCH family are thought to play a role in the lineage commitment but this 
process has not been clarified yet (Singer, 2002; Shanker et al., 2004). Therefore 
one can only speculate that the unknown protein is either an active contributor to 
the lineage commitment or that its different regulation in CD4 SP and CD8 SP 
thymocytes is the consequence of the lineage decision.  
 
The observation that the expression of the unknown protein is upregulated 
between the DN (78%) and the DP (94%) stage leads to the questions whether 
this protein is also differentially expressed in the four different DN-stages and 
when the cells start to express the unknown protein. Answers to these questions 
would give a hint to the nature of this unknown protein. Therefore it will be 
interesting to investigate the DN cells by flow cytometry with 1C5 together with 
CD4, CD8, CD25, CD44. With these latter four antibodies the DN cells can be 
differentiated.  
 
The finding that treatment of thymocytes with the cross-reacting antibody 1C5 
induces apoptosis in these cells pointed to a role of the unknown protein in the 
selection processes during thymocyte development, i.e. death by neglect and 
negative selection. These selection processes occur at the DP stage and lead to 
the elimination of thymocytes by apoptosis. Mature T cells are also subjected to 
apoptosis by peripheral deletion or activation induced cell death (AICD) (Green et 
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al., 2003). Therefore it is interesting to investigate whether mature T cells, i.e. 
1C5+ mature T cells, also die by apoptosis if they are treated with 1C5.  
 
The expression of the unknown protein seems to be dramatically downregulated 
after the thymocytes have left the thymus as mature T cells. Only ~1% of all CD3+ 
T cells or CD4+ and CD8+ subpopulations still express this protein. Whether this 
downregulation is really as dramatic as it appears now needs to be investigated in 
an additional experiment. Splenocytes of mice should be analysed pre- and 
postnatally at certain time intervals such as one week until the age of 6 weeks. 
1C5+ T cells are expected to be found in the spleen of embryos and right after 
birth. These 1C5+ T cells might then be diluted after the cells’ proliferation and 
remain at a level of 1% in the spleen.  
 
It is also probable that thymocytes need the unknown protein to be allowed to stay 
in the thymus and cease its expression when they are mature enough to leave the 
thymus. This hypothesis could also be clarified with the experiment described 
above. One would never find more than 1% of peripheral CD3+ cells being 1C5+. 
 
Interestingly the unknown protein seems to be upregulated when the cells are 
activated with a higher level of 1C5+ cells in the activated CD8+ subpopulation 
(8.6%) than in the activated CD4+ subpopulation (3.1%) mirrowing the difference 
which was found between CD4 SP and CD8 SP thymocytes.  
A small subset of activated T and B cells can re-enter the thymus. Therefore the 
upregulation of the unknown protein on activated B and T cells might enable them 
to move to and enter the thymus. This phenomenon could be monitored by 
injecting mice with 1C5+ activated, green-fluorescent protein (GFP)-transfected T 
and B cells. Part of these cells should be found in the thymus.  
 
The lower percentage of 1C5+ cells in the CD4+ subpopulation in the thymus and 
on activated CD4+ T cells compared to CD8+ cells might point to a lineage 
dependent expression of the unknown protein on CD4+ cells. This should be 
checked with additional markers differentiating CD4 SP cells in the thymus (for 
example heat stable antigen HSA+ versus more mature HSA- thymocytes) and 
activated mature CD4 T cells in the spleen (for example T helper 1 (TH1) versus 
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TH2 (by intracellular cytokine staining); regulatory T cells (TReg) (by the expression 
of CD25, FoxP3)). 
 
Having started with the hypothesis that 1C5 might be a marker for developing 
thymocytes, it was very surprising to see results exhibiting B cells with a higher 
percentage of 1C5+ cells (6%) than T cells in the spleen. Activated B cells 
upregulate the expression of the unknown protein to 35%, pointing to a role in the 
activation of mature lymphocytes, especially B cells.  
In order to investigate this possible role in activation, lymphocytes should be 
activated either in vitro with PMA/ionomycin or in vivo in an infection model. 
Lymphocytes activated in this way are expected to show a higher percentage of 
1C5+ cells in flow cytometric analysis.  
 
Interestingly 15% of the 1C5+ cells in the spleen are neither B nor T cells (data not 
shown). It will also be important to type these cells e.g. by their surface markers in 
flow cytometric analyses. 
 
The different expression of the unknown protein in the mature lymphocyte subsets 
of wt and LTβR-/- mice might be due to the changes and resulting problems in the 
immune system of adult LTβR-/- mice, described in the introduction, and might 
become important after determining the unknown protein.
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7. Future work 
All these interesting experiments described above only make sense after the 
unknown protein has been determined. 
There are three ways to determine the unknown protein. 
First, the isolation and sequencing of the protein from thymocytes, second, the 
cloning of the protein via screening of an expression library, and third, the 
generation of gene expression profiles of 1C5+ CD4 SP thymocytes in comparison 
with 1C5- CD4 SP thymocytes. 
 
RIPA buffer was used in order to isolate the unknown protein from thymocytes and 
the LTβR from L929 cells. The LTβR only was found in the insoluble fraction 
(chapter 4.4.4, figure 21) whereas the unknown protein was detectable neither in 
the soluble nor in the insoluble fraction (data not shown). Therefore another 
system should be chosen to lyse the cells and to get the unknown protein into 
solution.  
Immunoprecipitation might help to enrich the unknown protein. Separating the 
proteins on SDS-PAGE and detecting the unknown protein via western blot will 
help to identify the right band in the gel to be cut for further sequencing.  
Since it is not known at the moment whether 1C5 also detects the unknown 
protein if it is denatured, metabolic labeling of the cells with 35S before 
immunoprecipitation can circumvent this problem.  
Culturing cells in the presence of 35S-methionine will lead to the incorporation of  
the isoptope into the cellular proteins. Immunoprecipitation of the labeled proteins 
with 1C5 bound to proteinG-sepharose can be performed under native conditions 
also enabeling conformation-determined binding. The eluted 1C5+  35S-labeled 
proteins can be separated on SDS-PAGE and exposed to an autoradiographic film 
for the detection of the bands. In case there are multiple bands it would be helpful 
to work with 1C5+ cells in comparison with 1C5- cells from the same origin like for 
example 1C5+ and 1C5- CD4 SP thymocytes. The differentially appearing band(s) 
can be isolated for further sequencing.  
 
The screening of a prokaryotic mouse thymus cDNA expression library with the 
cross-reacting antibody 1C5 has failed for the first 1.6x105 pfu. Now it is necessary 
to check the technique with the prepared library which only expresses the mLTβR. 
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This library can also be used to test if the sensitivity of the antibody 1C5 is really 
high enough as to detect a certain protein in an expression library. Knowing that 
the antibody 1C5 is sensitive enough and can detect the prokaryotically expressed 
mLTβR does not guarantee that this is also the case for the unknown protein. 
If the antibody 1C5 is optimal for screening and the technique is established 
screening can be started again either with this prokaryotic mouse cDNA 
expression library or with the now available eukaryotic mouse thymocyte cDNA 
expression library. 
 
The fastest way to find the unknown protein seems to be the application of 
“proteomics” i.e. mouse gene expression arrays hybridized with cDNA of either 
1C5+ or 1C5- CD4 SP thymocytes. Looking for the expression profile of CD8 SP 
thymocytes which are nearly 100% 1C5+ can help to verify the findings.  
The upregulated genes in 1C5+ CD4 SP and CD8 SP thymocytes in comparison 
with 1C5- CD4 SP thymocytes finally need to be checked for the expression of the 
epitope on the surface of cells.  
 
The final prove for every found candidate in each of these experiments would be 
flow cytometric analysis on 1C5- cells after transfection with the candidate gene in 
an expression vector.
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8. Abstract 
Silvia Seegers  
 
Identification and Functional Characterization of a  
Mouse Lymphotoxin β-Receptor Like Protein 
 
Four different monoclonal rat anti mouse lymphotoxin β-receptor (mLTβR) 
antibodies were generated in order to study the expression patterns and molecular 
mechanisms that follow the activation of this receptor which belongs to the TNFR 
superfamily. One of these four antibodies, namely 1C5, cross-reacts with a protein 
on thymocytes of wildtype and LTβR-/- mice. Since thymocytes do not express the 
LTβR a similar receptor which might complement the LTβR on these cells was 
expected to be found.  
On the way to identify the unknown protein the epitope of the antibody 1C5 was 
narrowed down to the first twelve amino acids of the mature mLTβR. None of the 
other members of the TNFR superfamily contains this epitope. Homology 
searches led to a long list of matching candidates which need to be checked for 
plausibility. 
With flow cytometric analyses and treatment of thymocytes with 1C5 the following 
characteristics of the unknown protein were found.  
- Treatment with 1C5 induces apoptosis in thymocytes.  
- The unknown protein is LTβR-independently regulated during thymocyte 
development with a difference between the CD4 single-positive and the 
CD8 single-positive pathway. 
- Only a few mature T cells and B cells express the unknown protein. Its 
expression is upregulated when the cells are activated.  
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